EP2892918A2 - Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon - Google Patents

Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon

Info

Publication number
EP2892918A2
EP2892918A2 EP13773628.6A EP13773628A EP2892918A2 EP 2892918 A2 EP2892918 A2 EP 2892918A2 EP 13773628 A EP13773628 A EP 13773628A EP 2892918 A2 EP2892918 A2 EP 2892918A2
Authority
EP
European Patent Office
Prior art keywords
cdk4
cyclin
fusion protein
eukaryotic cells
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13773628.6A
Other languages
English (en)
French (fr)
Inventor
Eric Raspe
Pierre Roger
Katia COULONVAL
Sabine PATERNOT
Xavier BISTEAU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite Libre de Bruxelles ULB
Original Assignee
Universite Libre de Bruxelles ULB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite Libre de Bruxelles ULB filed Critical Universite Libre de Bruxelles ULB
Priority to EP13773628.6A priority Critical patent/EP2892918A2/de
Priority claimed from PCT/EP2013/068399 external-priority patent/WO2014037460A2/en
Publication of EP2892918A2 publication Critical patent/EP2892918A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Definitions

  • the present invention provides cyclin-dependent kinase 4 fusion proteins and uses thereof, especially assays for determining the activation status of endogenous cyclin- dependent kinase 4 (CDK4).
  • CDK4 acts as a master integrator in the G1 phase, coupling with the cell cycle mitogenic and antimitogenic signals as well as with their oncogenic counterparts in cancer cells.
  • CDK4 phosphorylates and inactivates the cell cycle/tumor suppressor proteins of the retinoblastoma (Rb) family (p105Rb, p107, and p130Rb2). This leads to both E2F- dependent transcription of essential cell cycle enzymes and regulators and assembly of the pre-replication complex.
  • the activation of CDK4 is a multistep process that requires the binding of a D-type cyclin (D1 , D2, or D3) and an activating phosphorylation in the T-loop at threonine 172 (Thr172 or T172) for CDK4.
  • D1 , D2, or D3 D-type cyclin
  • Thr172 or T172 threonine 172
  • CDK4 CDK-activating kinases
  • Thr172 Another possibility to study the phosphorylation of Thr172 involves the use of sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
  • SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
  • the phosphorylation on Thr172 of CDK4 does not affect the one-dimensional migration of the protein.
  • Two-dimensional electrophoresis after immunoprecipitation of CDK4 allows to separate the phosphorylated form based on the modification of electric charge.
  • this technique is laborious and requires large amounts of cells and reagents.
  • this technique is incompatible with high throughput analysis envisaged to identify novel CDK activating kinases or ways to interfere wth CDK4 activation.
  • an object of the present invention to provide an assay which allows to study the regulation of the phosphorylation of CDK4. Furthermore, it is an object of the present invention to provide assays which allow easy screening of novel CDK activating kinases and inhibitors thereof. Finally, it is an object of the present invention to provide a tool to generate and characterize antibodies to be used to directly detect CDK4 activation via phosphorylation.
  • the present invention provides new methods, tools, and assays addressing one or more of the above-mentioned problems of the prior art.
  • the present invention provides an in vitro assay for determining the activation status of endogenous cyclin-dependent kinase 4 (CDK4) in eukaryotic cells, said assay comprising the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • the present invention relates to an in vitro assay for determining the activation status of endogenous cyclin-dependent kinase 4 (CDK4) in a eukaryotic cell extract, said assay comprising the steps of:
  • the assays according to the present invention advantageously allow to study the mechanisms involved in the regulation of the activation of endogenous CDK4 for instance during cell cycle progression, in tumor cell lines, in tumors, etc. Moreover, such assays advantageously allow studying the regulation of the activation of endogenous CDK4 independently of the expression of cyclin D and/or the assembly of D-type cyclins with CDK4.
  • the present inventors have unexpectedly found that the assays embodying the principles of the present invention advantageously allow high throughput screening for activating kinases of CDK4 in an efficient and inexpensive way.
  • the assays of the invention allow studying the upstream signaling cascade of endogenous CDK4.
  • the assays of the present invention allow high throughput screening of siRNA libraries of the kinome to identify kinases involved in the activation of endogenous CDK4.
  • the assays of the present invention also allow high throughput screening of compounds able to activate or inactivate endogenous CDK4 activity. Since there is considerable evidence that the deregulation of cyclins and CDKs, in particular those controlling G1 progression may be involved in the development of many human cancers (Hall and Peters, 1996, Adv. Cancer Res. 68, 67-108; Sellers and Kaelin, 1997, J. Clin. Oncol., 15, 3301 -3312; Sherr, 1996, Science, 274, 1672-1677) and in the development of proliferative diseases such as restenosis or psoriasis, screening of inhibitory compounds of endogenous CDK4 activity is of major importance.
  • the present invention provides the use of a reporter molecule for determining the activation status of endogenous CDK4, wherein the reporter molecule comprises a cyclin D/cyclin-dependent-kinase 4 (CDK4) fusion protein.
  • CDK4 cyclin D/cyclin-dependent-kinase 4
  • said reporter molecule also comprises a tag, which can be used to isolate the reporter molecule from e.g. a cell extract.
  • the present invention provides a reporter molecule for determining the activation status of endogenous CDK4, wherein the reporter molecule comprises a cyclin D/CDK4 fusion protein and an Avi tag.
  • the Avi tag does not interfere with the function of the cyclin D/CDK4 fusion protein.
  • the present invention provides a reporter system comprising the reporter molecule as taught above and the biotin ligase BirA.
  • a reporter system advantageously allows purification of the reporter molecule, while retaining the functionality of the cyclin D/CDK4 fusion protein.
  • the present invention provides a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract, said kit comprising a eukaryotic cell line and a cyclin D/CDK4 fusion protein.
  • the present invention provides a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract, said kit comprising a eukaryotic cell line and a nucleic acid encoding a cyclin D/CDK4 fusion protein.
  • the present invention provides an assay for generating phospho- specific CDK4 binding molecules such as antibodies or fragments thereof, nanobodies or aptamers that specifically recognize the phosphorylated form of CDK4.
  • the present invention provides a tool for determining whether such a binding molecule, such as an antibody, a nanobody or an aptamer specifically recognizes the phosphorylated form of CDK4.
  • the invention further provides for the use of the cyclin D/CDK4 fusion tandemly purified from serum-stimulated eukaryotic cells as immunogen to create phospho CDK4-specific binding molecules.
  • a typical assay to identify and characterize phospho CDK4-specific binding molecules comprises the steps of: providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • eukaryotic cells maintained in a serum stimulated state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hyperphosphorylated form;
  • binding molecule or binding molecule preparation that preferably binds to the immobilized cyclin D/CDK4 fusion protein from serum-stimulated eukaryotic cells versus quiescent eukaryotic cells, thereby obtaining a phospho
  • CDK4-specific binding molecule or binding molecule preparation CDK4-specific binding molecule or binding molecule preparation.
  • said binding agent is selected from the group comprising: a specific antibody, antigen-binding antibody fragment, nanobody, affybody, an aptamer, a photoaptamer, a aptamer, a small molecule, an interacting partner, a specifically binding protein or peptide, a Darpin, an ankyrin, an isotopically labelled tracer or a ligand.
  • said suitable matrix is composed of a molecule coupled to a suitable support, said molecule being adapted to the used affinity purification tag fused to the cyclin D/CDK4 fusion protein.
  • said suitable support is selected from the group comprising: agarose, sepharose, polystyrene, polyethylene, gold (Biacore), 0.8 micron- sized iron, super-paramagnetic, hydrophobic, and polymer-encapsulated (non-exposed iron) beads (Nanolink,...), etc..
  • said suitable molecule is selected from the group comprising: avidin, streptavidin, neutravidin, CaptAvidin, Tamavidin, etc..
  • said suitable molecule When GST is used, said suitable molecule is glutathione. When MBP is used, said suitable molecule is amylose. When His-tag is used, said suitable molecules are Ni chelates. When Halo-tag is used, said suitable molecules are chloroalkane linkers attached to a variety of useful molecules, such as affinity handles, or solid surfaces. When Snap/Clip-tag is used, said suitable molecules are 0 6 -benzylguanine or 0 2 -benzylcytosine derivatives.
  • FIG. 1 schematically represents a reporter system according to an embodiment of the present invention comprising a reporter molecule according to an embodiment of the present invention and the biotine ligase (BirA) protein, and there under a construct comprising a nucleic acid sequence encoding a reporter system according to an embodiment of the present invention.
  • TET tetracyclin repressor
  • cyclin D/CDK4 fusion cyclin D/CDK4 fusion protein
  • Avi Avi tag
  • TEV tobacco etch virus cleavage site
  • EGFP enhanced green fluorescent protein
  • His poly-His purification tag
  • STOP stop codon
  • IRES internal ribosome entry site
  • BirA bifunctional protein biotine ligase BirA.
  • FIG. 2 schematically represents reporter systems according to different embodiments of the present invention.
  • CycD-CDK4 cyclin D/CDK4 fusion protein
  • Avi Avi tag
  • TEV tobacco etch virus cleavage site
  • EGFP enhanced green fluorescent protein
  • His poly-His purification tag
  • BirA bifunctional protein biotine ligase BirA
  • GST gluthathion-S- transferase
  • Luc luciferase.
  • FIG. 3 schematically represents different embodiments of an assay according to the present invention.
  • FIG. 4 schematically represents two embodiments of an assay according to the present invention.
  • FIG. 5 represents a graph plotting the percentage of cell nuclei labelled with bromodeoxyuridine as a function of time.
  • the graph illustrates the DNA synthesis for control cells rendered quiescent (dashed line) and cells stimulated at time point zero with 5% serum and 6 ng/ml insulin (full line).
  • FIG. 6 represents immunoblots illustrating cyclin protein expression levels and Rb phosphorylation as a function of time. Rb phosphorylation is recognized by the upward shift of the apparent molecular weight of the Rb protein detected with a mix of anti-Rb and anti-phospho-RB antibodies.
  • Cont control cells rendered quiescent; Serum: cells stimulated at time point zero with 5% serum and 6 ng/ml insulin; RB: retinoblastoma protein; RB-P: phosphorylated retinoblastoma protein; CycD1 : cyclin D1 ; CycD3: cyclin D3; CycA: cyclin A; CycB: cyclin B; and CycE: cyclin E.
  • FIG. 7A represents 2D immunoblots illustrating endogenous CDK4 abundance after immunoprecipitation with cyclin D1 (IP D1 ) or cyclin D3 (IP D3) in control cells rendered quiescent (Cont 8h) or 8h after stimulation of quiescent cells with 5% serum and 6 ng/ml insulin (Serum 8h).
  • FIG. 7B represents an immunoblot illustrating the Rb kinase activity of the immunoprecipitate determined by the phosphorylation status of a Rb fragment (Rb-P) after its incubation with the immunoprecipitate in the presence of ATP and in control cells rendered quiescent (indicated -) or after stimulation of quiescent cells with 5% serum and 6 ng/ml insulin (indicated +) for the indicated time periods.
  • FIG. 8 represents immunoblots illustrating the expression of the cyclin D/CDK4 fusion proteins detected with anti-CDK4, anti-cyclin D1 or anti-cyclin D3 , and illustrating the biotinylation status (Streptavidin-HRP) of HEK293T cells after transient transfection of the HEK293T cells with 1 : pBluescript, 2: pWFAvi_IBc_D1 (D1 + Be), 3: empty vector (Empty), 4: pWFAvi_IBc_D3L2K4 (D3L2K4 + Be), 5: pWFAvi_IBp_D1 (D1 + Bp), 6: pWFAvi_IBp_D1 L1 K4 (D1 L1 K4 + Bp), 7: pWFAvi_IBp_D3L2K4 (D3L2K4 + Bp).
  • FIG. 9A represents a graph plotting the input luciferase activity and the proportion of luciferase activity bound to streptavidin coated sepharose beads after purification of cell extracts of HEK293T cells transiently transfected with 1 : pBluescript; 2: pWFAvi_IBc_D3L2K4 (D3L2K4 + Be); 3: pWFAvi_IBp_D3L2K4 (D3L2K4 + Bp); 4: pWFAvi_IBp_D1 L1 K4 (D1 L1 K4 + Bp); 5: pWFAviJBcJuc (Luc + Be).
  • FIG. 10 represents immunoblots illustrating the expression of luciferase fused to the EGFP and the Avi-tag (luc), the expression of the tetracycline repressor (Tet), the expression of the endogeneous CDK4 (Endogeneous CDK4), the expression of the cyclin D3/CDK4 fusion with the linker 2 detected with the anti-CDK4 antibody (CDK4), the anti- cyclin D3 antibody, or the expression of EGFP with the anti-EGFP antibody (EGFP) as well as its biotinylation status (biotinylation) in cell extracts of MCF7 or MCF7KR cells after their infection with lentiviruses produced with the plasmids 1 : pWFAviJBcJuc (Luc + Be); 2, 4, 5: pWFAvi_IBc_D3L2K4 (D3L2K4 + Be); 3, 6, 7: pWFAvi_IBp_D3L2K4
  • FIG. 11A represents a graph plotting the input luciferase activity and the proportion of luciferase activity bound to streptavidin coated sepharose beads after purification of cell extracts of MCF7 cells infected with lentiviruses produced with vectors allowing the expression of untagged non-biotinylable luciferase, Avi-tagged biotinylable luciferase, or Avi-tagged biotinylable cyclin D3/CDK4 fusion.
  • MCF7 cells were rendered quiescent, and kept quiescent (indicated -) or stimulated at time point zero with 5% serum and 6 ng/ml insulin (indicated +), and allowed to proliferate for 16h in the presence of biotin before the preparation of cell extracts.
  • FIG. 11 B represents immunoblots illustrating the expression of the cyclin D3/CDK4 fusion with the linker 2 (noted D3L2K4) detected with the anti-CDK4 antibody, the endogeneous CDK4 expression (endogenous CDK4) and the kinase activity determined by the phosphorylation status of a Rb substrate detected with an anti-phospho-Rb antibody (Rb- P) in cell extracts of MCF7 cells infected with lentiviruses produced with vectors allowing the expression of untagged non-biotinylable luciferase, Avi-tagged biotinylable luciferase, or Avi-tagged biotinylable cyclin D3/CDK4 fusion.
  • FIG. 12 represents immunoblots illustrating the expression of the cyclin D3/CDK4 fusion with the linker 2 (noted fusion D3K4) detected with the anti-CDK4 antibody, the endogeneous CDK4 expression (noted CDK4) and the kinase activity determined by the phosphorylation status of a Rb substrate detected with an anti-phospho-Rb antibody (noted P-Rb826) in cell extracts of HCT1 16K7AS cells infected with lentiviruses produced with vectors allowing the expression of Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion hereafter named HCT1 16K7AS-V26.
  • HCT1 16K7AS-V26 unexposed to serum
  • 2 HCT1 16K7AS exposed to serum and DMSO used as vehicle for 5 hours
  • 3 HCT1 16K7AS-V26 exposed to serum and 1 -NMPP1 (noted NMPP1 ) to block the modified NMPP1 -inhibitable CDK7 expressed in the HCT1 16K7AS cells for 5 hours
  • 4 HCT1 16K7AS-V26 exposed to serum for 5 hours and DMSO used as vehicle for one additional hour
  • 5 HCT1 16K7AS-V26 exposed to serum for 5 hours and 1 - NMPP1 for one additional hour
  • 6 HCT1 16K7AS-V26 exposed to DMSO for one hour
  • 7 HCT1 16K7AS-V26 exposed to serum for 16 hours and DMSO used as vehicle for one additional hour
  • 8 HCT1 16K7AS-V26 exposed to serum for 16 hours and 1 -NMPP1 for one additional hour.
  • FIG. 13 represents immunoblots illustrating the expression of the luciferase or of the Avi- tagged luciferase/EGFP fusion detected with the anti-luciferase antibody (luc), the expression of the BirA biotin ligase detected with a anti-BirA antibody (BirA), the expression of the Avi-tagged cyclin D3/CDK4/EGFP fusions with the linker 2 or the linker 3 detected with the anti-EGFP antibody (EGFP) as well as their biotinylation status (streptavidin) in cell extracts of HEK293T cells transfected with vectors allowing the expression of Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion 0: no transfection; 1 : non biotinylable luciferase (Luc), 2 : biotinylable luciferase coupled to the BirA/mCherry fusion (AviLuc
  • FIG. 14 represents immunoblots illustrating the expression of the Avi-tagged cyclin D3/CDK4/EGFP fusions with the linker 2 or the linker 3 detected with the anti-CDK4 (noted CDK4) or the anti-CCND3 (noted CCND3) antibodies and the Rb-kinase activity determined by the phosphorylation status of a Rb substrate detected with an anti- phospho-Rb antibody (noted Rb826) and the shift in molecular weight observed upon phosphorylation of the Rb substrate detected anti-GST antibodiy (noted GST) in cell extracts of HEK293T cells transfected with vectors allowing the expression of Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion 0: no transfection; 1 : non biotinylable luciferase (Luc), 2 : biotinylable luciferase coupled to the BirA/mCherry fusion (A
  • FIG. 15 represents immunoblots illustrating the bi-dimensionnal separation of native or phosphorylated Avi-tagged cyclin D3/CDK4/EGFP fusions with the linker 3 digested with TEV and Prescission proteases detected with the anti-CDK4 (noted CDK4) or the anti- Phospho-CDK4 (noted PT172) antibodies in cell extracts of HEK293T cells transfected with vectors allowing the expression of the wild type Avi-tagged biotinylable cyclin D3/CDK4/EGFP fusion together with the BirA/mCherry fusion.
  • CDK4 anti-CDK4
  • PT172 anti- Phospho-CDK4
  • FIG. 16 represents immunoblots illustrating the expression (noted CDK4 and Luciferase), biotinylation (noted streptavidi) and Rb-kinase activity (noted P-Rb826) of the wild-type or T172A mutated Avi-tagged biotinylable cyclin D3/CDK4 fusion with the linker 3 compared to Avi-tagged biotinylable luciferase, or Avi-tagged biotinylable cyclin D3/CDK4 fusion with the linker 2 in cell extracts of MCF7 cells infected with lentiviruses produced with vectors allowing the expression of the corresponding transgenes.
  • FIG. 17 represents immunoblots illustrating the expression of the internally Avi-tagged cyclin D3/CDK4/Avi/EGFP or Luciferase/Avi/ fusions coupled or not to GFP detected with the anti-BirA (noted BirA), anti-GFP (noted GFP), anti-luciferase (noted Luciferase), the anti-CDK4 (noted CDK4) or the anti-CCND3 (noted CCND3) antibodies or with labeled streptavidin (noted streptavidin) in cell extracts of HEK293T cells transfected with vectors allowing the expression of internally Avi-tagged biotinylable cyclin D3/CDK4 or Luciferase/Avi/GFP fusions and the expression of the BirA biotin ligase as well as the Rb- kinase activity of the corresponding cell extracts (noted Rb-P Thr826) determined by the phosphorylation status of a Rb substrate detected with an
  • FIG. 18 represents immunoblots illustrating the Rb kinase activity determined by the phosphorylation status of a Rb substrate detected with an anti-phospho-Rb antibody in cell extracts obtained by the lysis with 6 different buffers together or not with glass/glass homogeneisation and/or sonication of HCT1 16K7AS cells infected with lentiviruses produced with vectors allowing the expression of Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion hereafter named HCT1 16K7AS-V26 unexposed to serum (noted Cont) or exposed to serum for 16 h (noted Serum 16h).
  • the buffers are presented in Example 22, Table 6.
  • FIG. 19 represents dot-blot images or quantification (noted Green/Red ratio) illustrating the Rb kinase activity determined by the phosphorylation status of a Rb substrate detected with an anti-phospho-Rb antibody in cell extracts of HCT1 16K7AS cells infected with lentiviruses produced with vectors allowing the expression of Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion hereafter named HCT1 16K7AS-V26 unexposed to serum (noted Cont); exposed to serum for 16 h (noted Serum 16h); or exposed to serum and 1 -NMPP1 for 16 h (noted Serum 16h + NMPP1 ) .
  • Cont Avi-tagged biotinylable cyclin D3/CDK4 fusion together with the BirA/mCherry fusion
  • FIG. 21 compares the Rb kinase activity (noted detection P-Rb826) immobilized on streptavidin-coated sepharose beads of cell extracts of HEK293T cells transfected with vectors allowing the expression of internally Avi-tagged biotinylable cyclin D3/CDK4/EGFP (noted ATGHis D3L3K4wt) or Luciferase/EGFP (noted ATGHis Luc) fusions or the corresponding constructs lacking the EGFP sequence between the TEV cleavage sites and the poly-histidine tag (noted ATHis D3L3K4 and ATHis Luc, respectively) and the expression of the BirA biotin ligase determined by the phosphorylation status of a Rb substrate immobilized on gluthation-coated plates detected by the DELFIA assay with an anti-phospho-Rb primary antibody and an Eu-coupled anti-mouse secondary antibody, the amount of cyclin D3/CDK4 fusion
  • FIG. 22 compares the Rb kinase activity (noted detection P-Rb) immobilized on streptavidin-coated plates of cell extracts of MCF7 cells infected with lentiviruses produced with vectors allowing the expression of wild type internally Avi-tagged biotinylable cyclin D3/CDK4/EGFP or internally Avi-tagged biotinylable Luciferase/EGFP fusions expressed together with BirA and the rTTA3 regulator in the presence of the inducer doxycyclin and serum cultivated in 96 well plates determined by the phosphorylation status of a Rb substrate detected by the Delfia assay with an anti- phospho-Rb primary antibody and an Eu-coupled anti-mouse secondary antibody, to the amount of cyclin D3/CDK4 fusion from the corresponding extracts immobilized on the streptavidin-coated plates (noted detection CCND3) detected by the Delfia assay with an anti-CCND3 primary antibody and an Eu-coup
  • the term 'about' is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.
  • the recitation of numerical ranges by endpoints includes all integer numbers and, where appropriate, fractions subsumed within that range (e.g. 1 to 5 can include 1 , 2, 3, 4 when referring to, for example, a number of elements).
  • the recitation of end points also includes the end point values themselves (e.g. from 1 .0 to 5.0 includes both 1.0 and 5.0).
  • any of the claimed embodiments can be used in any combination.
  • the terms “comprising”, “comprises” and “comprised of” as used herein are synonymous with “including”, “includes” or “containing”, “contains”, and are inclusive or open-ended and do not exclude additional, non-recited members, elements or method steps. It will be appreciated that the terms “comprising”, “comprises” and “comprised of” as used herein comprise the terms “consisting of", “consists” and “consists of.
  • the present inventors have realised the use of a cyclin D/CDK4 fusion protein, in particular the hypophosphorylated form of a cyclin D/CDK4 fusion protein to determine the activation status of endogenous CDK4.
  • the present invention provides the proof of concept of using a cyclin D/CDK4 fusion protein reporter molecule for assessing the endogenous CDK4 activation status in a cell or cellular extract, because it is shown that said cyclin D/CDK4 fusion protein mimics the activation status of the endogenous CDK4.
  • This invention thus provides new tools for assessing the activation status of endogenous CDK4 in a cell or cellular extract, and for screening candidate agents influencing said activation status.
  • candidate agents may be suitable anti-cancer or anti-proliferative agents, agents acting on CDK4 in general, or agents acting on CDK4-related disorders in general.
  • the assays will allow the further elucidation of the CDK4-pathway and the identification of new key components in cell cycle regulation.
  • the present invention relates to an in vitro assay for determining the activation status of endogenous cyclin-dependent kinase 4 (CDK4) in eukaryotic cells, said assay comprising the steps of: (a) providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein; (b) inducing proliferation of said eukaryotic cells; (c) isolating the cyclin D/CDK4 fusion protein from said eukaryotic cells; and (d) measuring the activation status of said isolated cyclin D/CDK4 fusion protein, thereby determining the activation status of endogenous CDK4 in said eukaryotic cells.
  • CDK4 cyclin-dependent kinase 4
  • the CDK4 part of the cyclin D/CDK4 fusion protein may be present in a hypophosphorylated form. In certain further embodiments, the CDK4 part of the cyclin D/CDK4 fusion protein may be present in a hyperphosphorylated form. Preferably, the CDK4 part of the cyclin D/CDK4 fusion protein is present in a hypophosphorylated form.
  • the determination of the activation status of endogenous CDK4 in eukaryotic cells can be based on the determination of the activation status of the isolated cyclin D/CDK4 fusion protein.
  • Changes in the activation state of said cyclin D/CDK4 fusion protein reflect changes in the status of the cellular components of the endogenous cyclin D/CDK4 signaling pathway and especially their ability to (de)phosphorylate CDK4.
  • Also disclosed herein is a method for determining the activation status of endogenous CDK4 in eukaryotic cells, said method comprising the steps of: (a) providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form; (b) inducing proliferation of said eukaryotic cells; (c) isolating the cyclin D/CDK4 fusion protein from said eukaryotic cells; and (d) measuring the activation status of said isolated cyclin D/CDK4 fusion protein, thereby determining the activation status of endogenous CDK4 in said eukaryotic cells.
  • the present assays or methods advantageously allow studying the regulation of the phosphorylation of endogenous CDK4 and the upstream mechanisms involved in the phosphorylation of endogenous CDK4. Moreover, such assays or methods allow studying the regulation of the phosphorylation of endogenous CDK4 independently of other steps of the activation process such as the expression of D-type cyclins and the assembly of D- type cyclins with CDK4.
  • activation status or “activation” can be used interchangeably herein.
  • the recitation “activation status of a cyclin-dependent kinase (CDK)” encompasses the phosphorylation status of the CDK as well as the ability of the CDK to perform its function, i.e., the ability of the CDK to phosphorylate one or more of its substrates.
  • the activation status of endogenous CDK4 in a cell or cellular extract may vary between different levels of activation ranging between an activation status wherein most of said CDK4 proteins are unphosphorylated, i.e., hypophosphorylated state, and an activation status wherein most of said CDK4 proteins are phosphorylated, i.e., hyperphosphorylated state.
  • CDK4 The following amino acids of CDK4 are involved in the activation of CDK4: Thr172 and Pro173.
  • Proline- directed kinases are hypothesized to be involved in the phosphorylation and activation of CDK4.
  • Activation of CDK4 requires the binding of D-type cyclins and may require additional steps such as the binding of p21 and/or p27 proteins for stability and nuclear import of CDK4.
  • Phosphorylation of endogenous CDK4 on Thr172 completes its activation.
  • the activation status of endogenous CDK4 may be determined by measuring the activation status of the cyclin D/CDK4 fusion protein, e.g. in a cell population to be tested or in a cellular extract thereof.
  • the recitation measuring the activation status of the cyclin D/CDK4 fusion protein may encompass detecting, quantifying, and/or monitoring the activation status of the cyclin D/CDK4 fusion protein.
  • the term "monitoring" generally refers to measuring the activation status over time. For instance, monitoring the activation status of endogenous CDK4 during cell cycle progression in a synchronized cell culture may be performed by measuring the activation status of the cyclin D/CDK4 fusion protein at one or more successive time points.
  • an assay or method for monitoring the activation status of endogenous CDK4 in said eukaryotic cells may comprise the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • the eukaryotic cells are maintained in a quiescent state before inducing proliferation of said eukaryotic cells.
  • the eukaryotic cells to be assayed will be at least partially synchronized.
  • the present assay or method advantageously allows studying the activation state of endogenous CDK4 during cell cycle progression of the eukaryotic cells.
  • endogenous CDK4 generally refers to CDK4 that originates from within a eukaryotic cell, cell line, or tissue.
  • cyclin D/CDK4 fusion protein refers to a single protein comprising a cyclin D and CDK4 coupled to each other with a linker.
  • cyclin D/CDK4 fusion protein or “cyclin D/CDK4 chimera” can be used interchangeably herein.
  • the cyclin D or D-type cyclin may be cyclin D1 , cyclin D2, or cyclin D3.
  • the cyclin D/CDK4 fusion protein may comprise eukaryotic cyclin D.
  • the eukaryotic cyclin D may be mammalian cyclin D, preferably human cyclin D.
  • the cyclin D/CDK4 fusion protein may comprise eukaryotic CDK4.
  • the eukaryotic CDK4 may be mammalian CDK4, preferably human CDK4.
  • Exemplary human nucleic acids, proteins, polypeptides or peptides as taught herein may be as annotated under NCBI Genbank (http://www.ncbi.nlm.nih.gov/) accession numbers given below.
  • NCBI Genbank http://www.ncbi.nlm.nih.gov/
  • accession numbers given below.
  • the entries below are presented in the form: Name (Code; Genbank accession number for one or more representative mRNA sequences (e.g., isoforms), followed by a period and the Genbank sequence version; Genbank accession number for one or more corresponding representative amino acid sequences (e.g., isoforms), followed by a period and the Genbank sequence version):
  • Cyclin-dependent kinase 4 also known as CMM3 or PSK-J3 (CDK4; NM_000075.3, NP_000066.1 )
  • Cyclin D1 also known as BCL1 ; PRAD1 ; U21 B31 ; D1 1 S287E (CCND1 ; NM_053056.2, NP_444284.1 )
  • Cyclin D2 also known as KIAK0002 (CCND2; NM_001759.3, NP_001750.1 )
  • Cyclin D3 (CCND3; NM_001 136126.1 , NM_001 136017.2, NP_00129598.1 , NP_00129489.1 )
  • cyclin D1 may comprise an amino acid sequence of SEQ ID NO. 1.
  • CDK4 may comprise an amino acid sequence of SEQ ID NO. 2.
  • cyclin D and CDK4 are connected by at least one linker.
  • the at least one linker preferably comprises sufficient glycine amino acids in order to permit a correct position and interaction between cyclin D and CDK4.
  • the linker may comprise or consist of an amino acid sequence of any one of L1 , i.e., ASKGGGGSGGGGSGGGGS (SEQ ID NO. 3), L2, i.e., ASKGGGGSLEVLFQPSR (SEQ ID NO. 4), ASKGGGGSLEVLFQGPSR (SEQ ID. NO. 5), or GGGGSGGGGSGGGGS (SEQ ID NO. 6) as described previously (Huston et al., 1988, Proc. Natl. Acad. Sci. USA, 85, 5879-5883).
  • the cyclin D and the CDK4 moieties of the cyclin D/CDK4 fusion protein can be separated by a linker including a protease sensitive cleavage site. Proteolytic dissociation of the cyclin D/CDK4 fusion protein followed by thermic denaturation of the lysate may allow specific purification of the CDK4 moiety. The phosphorylation status of this peptide may subsequently be determined using any anti-phospho-CDK4 or any phospho-TP antibody as well as by mass spectroscopy or any other relevant technique known to those skilled in the art.
  • Presence of the anti-phospho-CDK4 or the phospho-TP antibody on the immobilized CDK4 part of the fusion could be detected by the DELFIA technology as described herein, or by radioactive, colorimetric or chemiluminescence methods known to those skilled in the art.
  • the cyclin D/CDK4 fusion protein can perfectly be used to identify, characterize and validate any anti-phospho-CDK4 antibodies, nanobodies or aptamers.
  • the linker may comprise a protease cleavage consensus such as the Prescission site (GE Healthcare).
  • the linker may be an intein sequence.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D1 and CDK4 connected by the linker L1 ; said cyclin D/CDK4 fusion protein is referred to herein as D1 L1 K4.
  • the D1 L1 K4 may comprise an amino acid sequence of SEQ ID NO. 7.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D1 and CDK4 connected by the linker L2; said cyclin D/CDK4 fusion protein is referred to herein as D1 L2K4.
  • the D1 L2K4 may comprise an amino acid sequence of SEQ ID NO. 8.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D3 and CDK4 connected by the linker L1 ; said cyclin D/CDK4 fusion protein is referred to herein as D3L1 K4.
  • the D3L1 K4 may comprise an amino acid sequence of SEQ ID NO. 9.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D3 and CDK4 connected by the linker L2; said cyclin D/CDK4 fusion protein is referred to herein as D3L2K4.
  • the D3L2K4 may comprise an amino acid sequence of SEQ ID NO. 10.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D3 and CDK4 connected by the linker L3; said cyclin D/CDK4 fusion protein is referred to herein as D3L3K4.
  • the D3L3K4 may comprise an amino acid sequence of SEQ ID NO. 79, encoded by the nucleotide sequence of SEQ ID NO. 78.
  • the cyclin D/CDK4 fusion protein may comprise cyclin D1 and CDK4 connected by the linker L3; said cyclin D/CDK4 fusion protein is referred to herein as D1 L3K4.
  • the D1 L3K4 may comprise an amino acid sequence of SEQ ID NO. 81 , encoded by the nucleotide sequence of SEQ ID NO. 80.
  • any fusion protein, protein, polypeptide, or peptide such as any cyclin D/CDK4 fusion protein may also encompass functional fragments thereof.
  • fragment of a fusion protein, protein, polypeptide or peptide generally refers to N- terminally and/or C-terminally deleted or truncated forms of said fusion protein, protein, polypeptide or peptide, but largely retaining the functionality of the full-length reporter molecule.
  • any fusion protein, protein, polypeptide or peptide such as any cyclin D/CDK4 fusion protein may also encompass functional variants thereof, but largely retaining the functionality of the full-length reporter molecule.
  • variant of a nucleic acid, fusion protein, protein, polypeptide or peptide refers to nucleic acid, fusion proteins, proteins, polypeptides or peptides, the sequence ⁇ i.e., nucleotide sequence or amino acid sequence, respectively) of which is substantially identical (i.e., largely but not wholly identical) to the sequence of said recited nucleic acid, fusion protein, protein or polypeptide, e.g., at least about 80% identical or at least about 85% identical, e.g., preferably at least about 90% identical, e.g., at least 91 % identical, 92% identical, more preferably at least about 93% identical, e.g., at least 94% identical, even more preferably at least about 95%
  • a variant may display such degrees of identity to a recited nucleic acid, fusion protein, protein, polypeptide or peptide when the whole sequence of the recited nucleic acid, fusion protein, protein, polypeptide or peptide is queried in the sequence alignment (i.e., overall sequence identity). Also included among fragments and variants of a nucleic acid, fusion protein, protein, polypeptide or peptide are fusion products of said nucleic acid, fusion protein, protein, polypeptide or peptide with another, usually unrelated, nucleic acid, fusion protein, protein, polypeptide or peptide.
  • Sequence identity may be determined using suitable algorithms for performing sequence alignments and determination of sequence identity as know per se.
  • exemplary but non-limiting algorithms include those based on the Basic Local Alignment Search Tool (BLAST) originally described by Altschul et al., 1990 (J. Mol. Biol., 215, 403-10), such as the "Blast 2 sequences” algorithm described by Tatusova and Madden ,1999 (FEMS Microbiol.
  • a functional fragment and/or variant of a cyclin D/CDK4 fusion protein shall at least partly retain the biological activity of the cyclin D/CDK4 fusion protein.
  • a functional fragment and/or variant may retain at least about 20%, e.g., at least 30%, or at least about 40%, or at least about 50%, e.g., at least 60%, more preferably at least about 70%, e.g., at least 80%, yet more preferably at least about 85%, still more preferably at least about 90%, and most preferably at least about 95% or even about 100% or higher of the intended biological activity or functionality compared to the corresponding fusion protein, protein, polypeptide or peptide.
  • a functional fragment or variant would retain, to at least a certain degree, the ability to allow the determination of the activation status of CDK4.
  • eukaryotic cells refers to cells of a eukaryotic cell line such as an immortalized cell lines, tumour cell lines, or cell lines obtained by culturing primary tumour cells.
  • the eukaryotic cells may be mammalian cells.
  • the eukaryotic cells may be any cell line wherein the Rb pathway is functional.
  • the eukaryotic cells may be mammalian tumour cell lines such as for example MCF7, T98G, or HCT1 16 cells, or may be immortalized normal mammalian cell lines such as for example hTERT, HME, or MCF10A.
  • the eukaryotic cells as used herein typically and preferably denotes human cells, but may also encompass reference to non-human animals, preferably warm-blooded animals, more preferably vertebrates, even more preferably mammals, such as, e.g., non-human primates, rodents, canines, felines, equines, ovines, porcines, and the like.
  • hypophosphorylated form of the CDK4 part of the fusion protein encompasses the phosphorylation status of the CDK4 part or protein of the cyclin D/CDK4 fusion proteins wherein none of the cyclin D/CDK4 fusion proteins or less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, for example less than 5%, such as less than 4%, less than 3%, less than 2%, or less than 1 % of the cyclin D/CDK4 fusion proteins are phosphorylated.
  • hyperphosphorylated form of the CDK4 part of the fusion protein encompasses the phosphorylation state of the CDK4 part or protein of the cyclin D/CDK4 fusion proteins wherein all of the cyclin D/CDK4 fusion proteins or more than 50%, more than 60%, more than 70%, more than 80%, or more than 90%, for example more than 95%, such as more than 96%, more than 97%, more than 98%, or more than 99% of the cyclin D/CDK4 fusion proteins are phosphorylated.
  • the assay or method comprises providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a reporter molecule comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form.
  • the cyclin D/CDK4 fusion protein may be produced in eukaryotic cells.
  • the cyclin D/CDK4 fusion protein is produced in eukaryotic cells maintained in a quiescent state.
  • Producing the cyclin D/CDK4 fusion protein in eukaryotic cells maintained in a quiescent state advantageously allows producing directly the cyclinD/CDK4 fusion protein with the CDK4 part of the fusion protein in a hypophosphorylated form.
  • the eukaryotic cells may be maintained in a quiescent state by culturing the eukaryotic cells in deprived growth medium.
  • the eukaryotic cells may be maintained in a quiescent state by culturing the eukaryotic cells in the absence of serum.
  • the eukaryotic cells may be maintained in a quiescent state by culturing the eukaryotic cells in the absence of serum and hormones such as insulin.
  • the eukaryotic cells may be maintained in a quiescent state by culturing the eukaryotic cells in the absence of serum and in the presence of an anti-estrogen compound.
  • the eukaryotic cells may be maintained in a quiescent state by culturing the eukaryotic cells in the absence of serum and hormones and in the presence of an anti-estrogen compound.
  • the anti-estrogen compound preferably is fulvestrant (ICI-182,780, Faslodex, AstraZeneca), but can be equally replaced by tamoxifen, raloxifene, toremifene, or a Selective Estrogen Receptor Modulator (SERM) such as SP500263 known to those skilled in the art.
  • SERM Selective Estrogen Receptor Modulator
  • the assay or method comprises the step (b) inducing proliferation of the eukaryotic cells.
  • proliferation of the eukaryotic cells may be induced by culturing the eukaryotic cells in standard growth medium.
  • Proliferation of the eukaryotic cells may be induced by adding serum to deprived growth medium.
  • Proliferation of the eukaryotic cells may thus be induced by culturing the eukaryotic cells in growth medium comprising serum.
  • Proliferation of the eukaryotic cells may be induced by adding serum and hormones to deprived growth medium.
  • Proliferation of the eukaryotic cells may thus also be induced by culturing the eukaryotic cells in growth medium comprising serum and hormones such as insulin.
  • Suitable compounds or compositions to induce proliferation of eukaryotic cells may be serum substitutes such as Ultrose (Pall Corporation, NY, USA) or, Panexin NTA (PAN-Biotech GmbH, Germany), or one or more growth factors selected from platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin, or insulin-like growth factors (IGFs).
  • serum substitutes such as Ultrose (Pall Corporation, NY, USA) or, Panexin NTA (PAN-Biotech GmbH, Germany
  • PDGF platelet-derived growth factor
  • EGF epidermal growth factor
  • IGFs insulin-like growth factors
  • Culturing of eukaryotic cell lines is generally performed in the presence of a medium, commonly a liquid cell culture medium.
  • the medium will comprise a basal medium formulation as known in the art.
  • basal media formulations available, e.g., from the American Type Culture Collection, ATCC; or from Invitrogen, Carlsbad, California
  • MEM Eagle's Minimum Essential Medium
  • DMEM Dulbecco's Modified Eagle's Medium
  • alpha-MEM alpha modified Minimum Essential Medium
  • Basal Medium Essential (BME) Basal Medium Essential
  • BGJb F-12 Nutrient Mixture
  • Iscove's Modified Dulbecco's Medium IMDM
  • Compositions of the above basal media are generally known in the art and it is within the skill of one in the art to modify or modulate concentrations of media and/or media supplements as necessary for the cells cultured
  • basal media formulations contain ingredients necessary for mammalian cell development, which are known per se.
  • these ingredients may include inorganic salts (in particular salts containing Na, K, Mg, Ca, CI, P and possibly Cu, Fe, Se and Zn), physiological buffers (e.g., HEPES, bicarbonate), nucleotides, nucleosides and/or nucleic acid bases, ribose, deoxyribose, amino acids, vitamins, antioxidants (e.g., glutathione) and sources of carbon (e.g. glucose, sodium pyruvate, sodium acetate), etc.
  • inorganic salts in particular salts containing Na, K, Mg, Ca, CI, P and possibly Cu, Fe, Se and Zn
  • physiological buffers e.g., HEPES, bicarbonate
  • nucleotides e.g., nucleosides and/or nucleic acid bases
  • ribose e.g., deoxyribo
  • basal media can be supplied with one or more further components.
  • additional supplements can be used to supply the cells with the necessary trace elements and substances for optimal growth and expansion.
  • antioxidant supplements may be added, e.g., ⁇ -mercaptoethanol. While many basal media already contain amino acids, some amino acids may be supplemented later, e.g., L-glutamine, which is known to be less stable when in solution.
  • a medium may be further supplied with antibiotic and/or antimycotic compounds, such as, typically, mixtures of penicillin and streptomycin, and/or other compounds, exemplified but not limited to, amphotericin, ampicillin, gentamicin, bleomycin, hygromycin, kanamycin, mitomycin, mycophenolic acid, nalidixic acid, neomycin, nystatin, paromomycin, polymyxin, puromycin, rifampicin, spectinomycin, tetracycline, tylosin, and zeocin.
  • antibiotic and/or antimycotic compounds such as, typically, mixtures of penicillin and streptomycin, and/or other compounds, exemplified but not limited to, amphotericin, ampicillin, gentamicin, bleomycin, hygromycin, kanamycin, mitomycin, mycophenolic acid, nalidixic acid, neo
  • Plasma or serum may also be comprised in said media at a proportion (volume of plasma or serum/volume of medium) between about 0.5% and about 30%, preferably between about 1 % and about 15%.
  • the assay or method comprises the step (c) isolating the cyclin D/CDK4 fusion protein from the eukaryotic cells.
  • the isolation of the cyclin D/CDK4 fusion protein from the eukaryotic cells may be performed by isolating a sample of the eukaryotic cells, extracting the cyclin D/CDK4 fusion protein from the sample, and purifying the cyclin D/CDK4 fusion protein for instance using affinity purification.
  • a protein extract such as a protein extract comprising the cyclin D/CDK4 fusion protein, from eukaryotic cells is well known by the skilled man in the art and illustrated in the example section.
  • the activation status of the isolated cyclin D/CDK4 fusion protein CDK4 may be measured by quantifying the Rb kinase activity of the isolated cyclin D/CDK4 fusion protein. In certain further embodiments, the activation status of the isolated cyclin D/CDK4 fusion protein CDK4 may be measured by detecting the phosphorylation status of the isolated cyclin D/CDK4 fusion protein, preferably by detecting phosphorylation of the isolated cyclin D/CDK4 fusion protein on T172.
  • the Rb kinase activity of the isolated cyclin D/CDK4 fusion protein may be assessed by incubating the isolated cyclin D/CDK4 fusion protein with retinoblastoma (Rb) protein or a fragment thereof before quantifying the phosphorylation level of the Rb protein or a fragment thereof.
  • Rb retinoblastoma
  • the quantification of the phosphorylation level of the Rb protein or a fragment thereof may be achieved by quantifying the amount of radioactively labelled phosphor incorporated in Rb.
  • the quantification of the phosphorylation level of the Rb protein or a fragment thereof may be achieved by specifically detecting the phosphorylated form of Rb using a molecule specifically detecting the phosphorylated form of Rb, for example an antibody, a nanobody, or an aptamer specifically detecting the phosphorylated form of Rb.
  • the quantification of the phosphorylation level of the Rb protein or a fragment thereof may also be achieved by mass spectroscopy.
  • the phosphorylation of Rb can be evaluated by the shift in 1 D gel electrophoresis migration as exemplified in figures 6 and 17.
  • the activation status of the isolated cyclin D/CDK4 fusion protein CDK4 may be measured by detecting the phosphorylation status of the isolated cyclin D/CDK4 fusion protein.
  • the quantification of the phosphorylation state of the isolated cyclin D/CDK4 fusion protein may be achieved using a molecule specifically detecting phosphorylated forms of CDK4.
  • the molecule specifically detecting phosphorylated forms of CDK4 may be an antibody, a nanobody, or an aptamer.
  • the molecule specifically detecting phosphorylated forms of CDK4 may interact with a phosphorylated threonine followed by a proline, or may interact with the phosphorylated T172 of CDK4.
  • the activation status of the isolated cyclin D/CDK4 fusion protein may be measured by detecting the phosphorylation of the cyclin D/CDK4 fusion protein on T172.
  • Detection of the phosphorylation of the isolated cyclin D/CDK4 fusion protein on T172 may be achieved on the immobilized native form of the isolated cyclin D/CDK4 fusion protein or may be achieved on the denaturated form of the isolated cyclin D/CDK4 fusion protein for instance after its proteolytic cleavage and immobilisation on a suitable matrix.
  • the quantification of phosphorylation level of the isolated cyclin D/CDK4 fusion protein on T172 may be achieved using a molecule specifically detecting the T172-phosphorylated form of the cyclin D/CDK4 fusion protein.
  • the molecule specifically detecting the T172- phosphorylated form of the cyclin D/CDK4 fusion protein may be an antibody, a nanobody, or an aptamer.
  • the quantification of the phosphorylation of the isolated cyclin D/CDK4 fusion protein, in particular phosphorylation of T172 on isolated cyclin D/CDK4 fusion protein, may also be achieved by mass spectroscopy.
  • the activation status of the isolated cyclin D/CDK4 fusion protein may be measured using fluorescent detection technology such as Dissociation-Enhanced Lanthanide Fluorescent Immunoassay (DELFIA, Perkin-Elmer).
  • DELFIA spectroscopy is a technique of time-resolved fluorescence (delayed transmission over the excitation). Fluorescence spectroscopy resolved in time is possible when the fluorochrome has a long disintegration time.
  • the DELFIA technology exploits the unique properties of lanthanide fluorescence. These fluorophores have very long decay time and thus continue to emit after stopping excitation.
  • the lanthanides also have a large difference in wavelength between the excitation light and the emission light (Stokes' shift), which makes the system very sensitive due to the virtual absence of background noise.
  • the europium ion (Eu3 +) is the most used lanthanide in the DELFIA system and has, like the other lanthanides, a single emission peak, which facilitates the possibility of multiple detections.
  • the fluorescence of the lanthanide is measured at a time when the non-specific fluorescence is almost zero i.e., 400-800 ⁇ 8 after cessation of excitation.
  • the activation status of the isolated cyclin D/CDK4 fusion protein may be measured by the DELFIA technology wherein two different antibodies with two lanthanides are used.
  • a first lanthanide may be coupled to an antibody directed against the phosphorylated CDK4 protein of the isolated cyclin D/CDK4 fusion protein and a second lanthanide may be coupled to an antibody against the total cyclin D/CDK4 fusion protein for instance against the CDK4 part of the fusion protein.
  • the antibodies may be added to the reporter molecule and an activation solution may be added. The low pH of the activation solution decouples the lanthanide antibody in a few minutes.
  • the free lanthanide will form a chelate with the components of the activating solution in a protective micelle.
  • the chelates can be excited and the fluorescence emission of two filters measured: a filter or channel passing the wavelength of the emission peak of the first lanthanide and a filter or channel passing the wavelength of the emission peak of the second lanthanide.
  • the fluorescence ratio between the two channels can be measured and hence the ratio of the phosphorylated cyclin D/CDK4 fusion protein versus total cyclin D/CDK4 fusion protein may be determined.
  • an assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 may comprise, prior to or upon inducing proliferation of said eukaryotic cells, the step of incubating or contacting said eukaryotic cells with at least one candidate agent.
  • This step advantageously allows to identify activating kinases of endogenous CDK4 such as proline-directed kinases or to identify inhibitory molecules acting upstream of endogenous cyclinD/CDK4 complexes or directly inhibiting the activation of endogenous cyclin D/CDK4 complexes.
  • the assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 in eukaryotic cells may comprise the steps of: providing eukaryotic cells, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein;
  • the assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 in eukaryotic cells may comprise the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • the assays or methods as taught herein may comprise measuring the activation status of the cyclin D/CDK4 fusion protein in comparison with a control.
  • the control may be said eukaryotic cells left untreated.
  • CDK4-related diseases may encompass any disease or disorder wherein the activation of CDK4 is deregulated such as certain types of cancer, e.g. gliomas and sarcomas, and proliferative diseases or disorders, e.g. restenosis or psoriasis.
  • the assay can be used to screen molecules or therapeutics for their effect on cell-proliferation. That is, when a hypophosphorylated fusion construct is used, increase in phosphorylation in presence of the candidate agents points towards stimulation of proliferation.
  • the assay furthermore allows screening molecules or therapeutics able to inhibit CDK4 activating kinases.
  • CDK4 activating kinases may be constitutively active.
  • the present assays or methods as taught herein may advantageously allow screening candidate agent able to inhibit or inactivate these CDK4 activating kinases.
  • the assays embodying the principles of the present invention advantageously allow high throughput screening for activating kinases of endogenous CDK4 in an efficient and inexpensive way.
  • the present assays hence allow studying the upstream signalling cascade of endogenous CDK4.
  • the assays of the present invention allow high throughput screening of siRNA or mRNA libraries of the kinome to identify kinases involved in the inhibition or activation of endogenous CDK4.
  • the present assays also allow high throughput screening of compounds able to inactivate the endogenous cyclin D/CDK4 complex or one or more of the upstream kinases.
  • the assays also allow determining the impact of the overexpression of any kinase or signalling molecule on the activation of endogenous CDK4, by e.g. screening a cDNA or mRNA library of candidate proteins.
  • the Broad Institute and MIT Human Kinase ORF collection from Addgene consisting of 559 distinct human kinases and kinase-related protein open reading frames (ORFs) in pDONR-223 Gateway® Entry vectors can be an important instrument in this respect.
  • the at least one candidate agent may be selected from the group consisting of a biological sample, a protein, a nucleic acid, an siRNA, a microRNA, a chemical compound, and a small molecule.
  • the biological sample may be a cell extract such as a eukaryotic cell extract or a prokaryotic cell extract, tumor biopsy, tumor exudates, blood etc.
  • Suitable non-limiting examples of chemical compounds include roscovitine and its derivatives such as CR8, PD033299, BS-181 , or combinations thereof. Libraries of specific and non-specific kinase inhibitors are commercially available (Selleckbio, SelleckChem, enzolifesciences, Cayman chemicals, Millipore,Tocris, aachembio, vichem synmedchem, etc. Suitable non-limiting examples of siRNA or microRNA include RNA molecules which are directed against candidate activating kinases of CDK4.
  • Possible candidate activating kinases of CDK4 include proline-directed kinases (PDK); mitogen-activated protein (MAP) kinases such as c-Jun N-terminal kinases (JNKs) and cyclin-dependent kinases (CDKs) such as CDK1 to CDK20; glycogen synthase kinases (GSKs) such as GSK-3, Homeodomain-interacting protein kinases (HIPKs); and kinases related to both MAPKs and CDKs.
  • PDK proline-directed kinases
  • MAP mitogen-activated protein
  • JNKs c-Jun N-terminal kinases
  • CDKs cyclin-dependent kinases
  • CDK1 to CDK20 CDK1 to CDK20
  • GSKs glycogen synthase kinases
  • HIPKs Homeodomain-interacting protein kinases
  • a suitable siRNA library although partial is the CMGC Kinase G-004500 of Dharmacon.
  • the G-03505_Human_siGENOME_Protein_Kinase of Dharmacon is a suitable alternative as it cover all known kinases of the human genome.
  • Alternative libraries are also provided by Qiagen (FlexiPlate siRNA Gene Family), Invitrogen (Silencer Select Human Kinase siRNA Library V4), Sigma (MISSION® siRNA Human Kinase Panel), Ambion (SilencerTM Kinase siRNA Library) Abnova (Kinase siRNA library SRL003), Bioneer (AccuTarget Human Kinase siRNA Set),
  • the present invention relates to an in vitro assay for determining the activation status of endogenous cyclin-dependent kinase 4 (CDK4) in a eukaryotic cell extract, said assay comprising the steps of: (a) providing a cyclin D/CDK4 fusion protein; (b) contacting the cyclin D/CDK4 fusion protein with a eukaryotic cell extract; and (c) measuring the activation status of said cyclin D/CDK4 fusion protein, thereby determining the activation status of endogenous CDK4 in said eukaryotic cell extract.
  • the CDK4 part of the cyclin D/CDK4 fusion protein may be present in a hypophosphorylated form.
  • the CDK4 part of the cyclin D/CDK4 fusion protein may be present in a hyperphosphorylated form.
  • the CDK4 part of the cyclin D/CDK4 fusion protein is present in a hypophosphorylated form.
  • the above recitation "determining the activation status of endogenous CDK4 in said eukaryotic cell extract" may encompass determining the capability or potential of the cell extract to activate the cyclin D/CDK4 fusion protein.
  • Also disclosed herein is a method for determining the activation status of eukaryotic CDK4, said method comprising the steps of: (a) providing a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form; (b) contacting the cyclin D/CDK4 fusion protein with a eukaryotic cell extract; and (c) measuring the activation status of said cyclin D/CDK4 fusion protein, thereby determining the activation status of endogenous CDK4 in said eukaryotic cell extract.
  • the present assays or methods advantageously allow to study the regulation of the phosphorylation of endogenous CDK4 in a eukaryotic cell extract, for instance in a eukaryotic cell extract prepared from a tumor.
  • the present assays or methods allow studying the regulation of the phosphorylation of endogenous CDK4 in a eukaryotic cell extract independently of the expression of D-type cyclins and the assembly of cyclin D with CDK4.
  • the present assay or method comprises the step of (a) providing a cyclin D/CDK4 fusion protein.
  • the CDK4 part of the fusion protein may be present in a hyperphosphorylated form.
  • the CDK4 part of the fusion protein is present in a hypophosphorylated form.
  • a cyclin D/CDK4 fusion protein may be provided by producing the cyclin D/CDK4 fusion protein, extracting the cyclin D/CDK4 fusion and purifying the cyclin D/CDK4 fusion.
  • the cyclin D/CDK4 fusion protein provided in the assays or methods as taught herein may be produced in prokaryotic cells.
  • the cyclin D/CDK4 fusion protein provided in the assays or methods as taught herein may be produced in eukaryotic cells and subsequently dephosphorylated by a phosphatase such as the lambda phosphatase. This advantageously allows obtaining eukaryotic cells wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form.
  • the cyclin D/CDK4 fusion protein provided in the assays or methods as taught herein may also be produced in eukaryotic cells maintained in a quiescent state.
  • Producing the cyclin D/CDK4 fusion protein in eukaryotic cells maintained in a quiescent state advantageously allows producing directly the cyclinD/CDK4 fusion protein with the CDK4 part of the fusion protein in a hypophosphorylated form.
  • the cyclin D/CDK4 fusion protein may be extracted from the cells such as prokaryotic cells or eukaryotic cells by any method known in the art.
  • the cyclin D/CDK4 fusion protein may be purified by affinity purification or using the Avi tag or any other tag coupled to the cyclin D/CDK4 fusion protein. Methods for affinity purification are known in the art and are illustrated in the example section.
  • the present assay or method comprises the step of (b) contacting the cyclin D/CDK4 fusion protein with a eukaryotic cell extract.
  • the eukaryotic cell extract may be obtained from a eukaryotic cell line such as an established cell line or a tumor cell line.
  • the eukaryotic cell extract may also be obtained from tissue such as a tumor biopsy, an exudate, etc.
  • the eukaryotic cell extract may be obtained from untreated eukaryotic cells.
  • the eukaryotic cell extract may also be obtained from synchronized eukaryotic cells.
  • the eukaryotic cell extract may be obtained from eukaryotic cells incubated with at least one candidate agent.
  • an assay or method as taught herein may comprise obtaining the eukaryotic cell extract from untreated eukaryotic cells.
  • Such cell extract obtained from untreated cells may advantageously allow determining the activation status of endogenous CDK4 in tumour cell lines, tumours, tumour-associated fluids or tissues, pleural effusions, exudates etc.
  • an assay or method as taught herein may comprise obtaining the eukaryotic cell extract from synchronized eukaryotic cells.
  • Such cell extract obtained from synchronized eukaryotic cells may allow determining the activation status of endogenous CDK4 during cell cycle progression.
  • Eukaryotic cells may be synchronized by any technique known in the art for cell cycle synchronization such as nutrient deprivation or nutritional blockage, the addition of chemical compounds for instance arresting the cells at the G1 -S or G2-M cell cycle transitions, or cell sorting.
  • an assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 may comprise obtaining the eukaryotic cell extract from eukaryotic cells incubated with at least one candidate agent.
  • an assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • an assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 may comprise obtaining a eukaryotic cell extract and incubating the eukaryotic cell extract with at least one candidate agent.
  • an assay or method for evaluating the effect of a candidate agent on the activation status of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • the assays or methods as taught herein may comprise measuring the activation status of the cyclin D/CDK4 fusion protein in comparison with a control.
  • the control may be a cell extract of said eukaryotic cells left untreated or may be said eukaryotic cell extract left untreated.
  • an assay or method for identifying an activating kinase of endogenous CDK4 in eukaryotic cells may comprise the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • an assay or method for identifying an activating kinase of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • Such assays or methods may advantageously allow identifying activating kinases of endogenous CDK4 such as proline-directed kinases, or identifying kinases involved in the upstream pathway of the activation of endogenous cyclin/CDK4 complexes.
  • the assay or method for identifying a chemical compound affecting the activation status of endogenous CDK4 in eukaryotic cells may comprise the steps of: providing eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • an assay or method for identifying a chemical compound affecting the activation status of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • an assay or method for identifying a chemical compound, such as a small molecule, affecting the activation status of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • identifying whether the chemical compound affects the activation status of endogenous CDK4 in said eukaryotic cell extract by comparing the activation status of said isolated cyclin D/CDK4 fusion protein between said eukaryotic cell extract incubated with the chemical compound and a eukaryotic cell extract left untreated.
  • assays or methods may allow identifying chemical compounds activating or inhibiting endogenous cyclin D/CDK4 complexes or its activation by another kinase.
  • the candidate agent may for instance be a candidate activating kinase of CDK4.
  • the eukaryotic cells may be stably or transiently transfected with a nucleic acid encoding a candidate activating kinase of CDK4.
  • the expression of the nucleic acid encoding a candidate activating kinase of CDK4 is controlled by an inducible promoter.
  • an assay or method for identifying an activating kinase of endogenous CDK4 in eukaryotic cells may comprise the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form, and said eukaryotic cells comprising a nucleic acid encoding a candidate activating kinase;
  • an assay or method for identifying an activating kinase of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • eukaryotic cells comprising a nucleic acid encoding a candidate activating kinase
  • said eukaryotic cells may comprise an expression vector, preferably an inducible expression vector, comprising a nucleic acid sequence encoding a candidate activating kinase and the expression of the candidate activating kinase may be induced in said eukaryotic cells.
  • an assay or method for identifying an activating kinase of endogenous CDK4 in eukaryotic cells may comprise the steps of:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form; inducing in said eukaryotic cells the expression of a candidate activating kinase with an expression vector, preferably an inducible expression vector;
  • an assay or method for identifying an activating kinase of endogenous CDK4 in a eukaryotic cell extract may comprise the steps of:
  • a candidate activating kinase inducing in a eukaryotic cells the expression of a candidate activating kinase with an expression vector, preferably an inducible expression vector;
  • the expression vector is an inducible vector.
  • Such assays or methods may advantageously allow identifying activating kinases of endogenous CDK4 such as proline-directed kinases, or identifying kinases involved in the upstream pathway of the activation of endogenous cyclin/CDK4 complexes.
  • the candidate agent may also be any industrial product or material, for which it is important to know its effect on CDK4 signalling, especially proliferation-related signaling.
  • the assays or methods as taught herein may advantageously allow evaluating or testing the effect of the industrial product or material on the CDK4 activation status in eukaryotic cells or cell lines.
  • the assays or methods as taught herein may allow determining whether an industrial product or material influences the cell cycle progression of eukaryotic cells or cell lines.
  • the assays or methods as taught herein may hence allow determining the toxicity of the industrial product or material in eukaryotic cells or cell lines.
  • the present invention relates to a reporter molecule configured for determining the activation status of endogenous CDK4, wherein said reporter molecule comprises a cyclin D/cyclin-dependent-kinase 4 (CDK4) fusion protein and an Avi tag.
  • said reporter molecule comprises from its amino terminus to its carboxyl terminus: a cyclin D/cyclin-dependent-kinase 4 (CDK4) fusion protein and an Avi tag.
  • CDK4 protein of the cyclin D/CDK4 fusion protein is directly coupled to the Avi tag.
  • the Avi tag is part of the dual SB1 -Avi tag for tandem purification.
  • Cyclin D may be selected from cyclin D1 , cyclin D2, or cyclin D3.
  • said reporter molecule comprises an amino acid sequence of any one of SEQ ID No. 7, SEQ ID No. 8, SEQ ID No. 9, SEQ ID No. 10, SEQ ID NO. 79, or SEQ ID NO. 81 .
  • the reporter molecule as taught herein may further comprise one or more purification tags selected from Avi tag, poly-histidine tag, glutathion-S-transferase (GST), maltose binding protein (MBP), SNAP/CLIP tag, Halo tag, Strep tag, and the synaptobrevin SB1 , Flag, V5, Myc, HA epitopes. These tags may advantageously allow additional purification steps of the reporter molecule such as affinity purification.
  • the reporter molecule as taught herein may comprise a cleavable sequence.
  • the one or more purification tags may be separated from the cyclin D/CDK4 fusion protein by a cleavable sequence.
  • the cyclin D/CDK4 fusion protein or the one or more purification tags may comprise a cleavable sequence such as a sequence cleavable by a protease.
  • the cleavable sequence may be a tobacco etch virus (TEV) sequence such as TEV1 or TEV2.
  • TEV tobacco etch virus
  • the cleavable sequence may also be an intein sequence.
  • the reporter molecule as taught herein may comprise a reporter protein such as an enhanced green fluorescent protein (EGFP) or Luciferase.
  • said reporter molecule may comprise an amino acid sequence of any one of SEQ ID No. 1 1 , SEQ ID NO. 12, SEQ ID NO. 13, and SEQ ID No. 14.
  • the present invention also provides a reporter system comprising the reporter molecule as taught herein and the biotin ligase BirA.
  • biotin ligase BirA refers to the E. coli bifunctional biotin- [acetylCoA carboxylase] holoenzyme synthetase/ DNA-binding transcriptional repressor, bio-5'-AMP-binding, also known as BirA, bioR; dhbB; ECK3965; JW3941 (bir A; NC_000913.2; NP_418404.1 ), or a functional fragment or variant thereof such as a humanized version of the E. coli BirA protein.
  • said reporter system may comprise a biotin ligase BirA encoded by a nucleic acid sequence of any one of SEQ ID No. 15 and SEQ ID No. 17.
  • said reporter system may comprise an amino acid sequence of any one of SEQ ID No. 16 and SEQ ID No. 18.
  • Expression vectors can be transiently introduced in recipient cells by common electroporation methods or transfection methods such as the calcium phosphate method, the lipofection method, or the use of polyethylenimine (PEI) derivatives.
  • Linearized expression vectors can be used to generate stable cell lines provided that they bear appropriate selection markers.
  • Transient expression of transgenes can also be insured by the use of modified baculovirus vectors in which insect promoter sequences driving the expression of the transgenes are replaced by promoter sequence active in mammalian cells.
  • Adenoviruses or adenovirus-associated viruses are an alternative way to transiently express the desirable transgenes in mammalian cells.
  • cell lines stably expressing the desired transgenes are generated using lentiviral vectors or any other suitable retroviruses.
  • all components required for the assay may be present in a single viral vector.
  • This vector contains an expression module for the Avi-tagged cyclin D/CDK4 fusion protein under the control of a tet response element.
  • This vector also contains a bicistronic expression module under the control of a constitutive promoter. This bicistronic module drives the expression of the rTTA3 regulator separated by an IRES sequence from the BirA biotine ligase fused to a selection marker. The rTTA3 regulator will induce the expression of the cyclin D/CDK4 fusion protein following the addition of the doxycycline molecule to the cells.
  • the BirA biotine ligase may biotinylate the Avi-tag of the cyclin D/CDK4 fusion protein.
  • the mCherry sequence fused to the BirA biotine ligase codes for a fluorescent protein usable to determine the proportion of cells expressing the rTTA3 and the BirA/mCherry fusion, and to enrich this population by Fluorescence-activated cell sorting (FACS).
  • FACS Fluorescence-activated cell sorting
  • the BirA biotine ligase may be fused in frame to any antibiotic resistance gene in a way that does not interfere with its ability to biotinylate the Avi-tag. Selection of the population expressing the transgene occur by incubating the cells with the appropriate antibiotic rendered inactive by the above mentioned resistance gene.
  • the cyclin D/CDK4 fusion protein is part of a bicistronic expression module under the control of a constitutive promoter.
  • the cyclin D/CDK4 fusion protein is separated by an IRES sequence from the BirA biotine ligase fused to a selection marker as described herein.
  • the rTTA3 regulator may be expressed under the control of a constitutive promoter. It may be part of a bicistronic expression module in which the rTTA3 regulator is separated by an IRES sequence from a selection marker. This marker can be a fluorescent protein, or a protein conferring to the cells the resistance to an antibiotic. The fluorescent protein will be used to determine the proportion of cells expressing the rTTA3 and to enrich this population by FACS sorting.
  • the rTTA3 regulator may acts in trans to drive, in the presence of doxycyclin, the expression of an expression module introduced in the cell by a second vector.
  • This module includes the Avi-tagged cyclin D/CDK4 fusion protein and the BirA/mCherry fusion separated from the former by an IRES sequence.
  • the BirA biotine ligase may biotinylate in cis the Avi-tag of the cyclin D/CDK4 fusion protein.
  • the mCherry sequence fused to the BirA biotine ligase codes for a fluorescent protein usable to determine the proportion of cells expressing the rTTA3 and the BirA mCherry fusion and to enrich this population by FACS sorting.
  • the BirA biotine ligase can be fused in frame to any antibiotic resistance gene in a way that does not interfere with its ability to biotinylate the Avi-tag.
  • Selection of the population expressing the transgene occur by incubating the cells with the appropriate antibiotic rendered inactive by the above mentioned resistance gene.
  • Such resistance gene can confer resistance to neomycin, blasticidin, puromycin, zeocin, hygromycin in a non-limitative way.
  • the expression of BirA/mCherry fusion present on the second vector can be controlled by a constitutive promoter.
  • the BirA biotine ligase can be fused in frame to any antibiotic resistance gene in a way that does not interfere with its ability to biotinylate the Avi-tag. Selection of the population expressing the transgene can occur by incubating the cells with the appropriate antibiotic rendered inactive by the above mentioned resistance gene.
  • the rTTA3 present on the first vector can be replaced by the BirA biotine ligase or its fusion with a fluorescent molecule or an antibiotic resistance gene. If the rTTA3 present on the first vector is be replaced only by the BirA biotine ligase, the vector should also include either a fluorescent molecule or an antibiotic resistance gene under the control of an IRES sequence or a constitutive promoter. In any of these cases, the rTTA3 regulator can be expressed under the control of a constitutive promoter located on the second vector. In this vector, the rTTA3 regulator sequence will be followed by an IRES sequence driving the expression of a fluorescent molecule or an antibiotic resistance gene.
  • the second vector will also include an expression module for the Avi- tagged cyclin D/CDK4 fusion under the control of a tet response element.
  • Expression of the Avi-tagged cyclin D/CDK4 fusion can be regulated in cis by the rTTA3 regulator according to the presence of doxycyclin.
  • the expressed Avi-tagged cyclin D/CDK4 fusion can in this case be constitutively biotinylated in trans by the BirA biotine ligase expressed from the first vector.
  • the expression of the Avi-tagged cyclin D/CDK4 fusion protein can be driven by a constitutive promoter on the second vector.
  • This second vector will also drive the expression of a fluorescent molecule or an antibiotic resistance gene either through the use of an IRES sequence following the Avi-tagged cyclin D/CDK4 fusion sequence or through the use of a second independent constitutive promoter.
  • the Avi-tagged cyclin D/CDK4 fusion can be constitutively expressed and biotinylated in trans by the BirA biotine ligase expressed from the first vector.
  • all components required for the assay may be present on three distinct viral vectors.
  • both the regulation of the expression of the Avi-tagged cyclin D/CDK4 fusion by the rTTA3 regulator according to the presence of doxycyclin and its biotinylation by BirA will occur in trans.
  • three different fluorescent molecules or antibiotic resistance genes may be expressed together with the respective transgenes via an IRES sequence.
  • the expression of fluorescent molecules or antibiotic resistance genes may be driven by independent constitutive promoters.
  • BirA biotine ligase sequence of the vector is replaced by BirA/mCherry fusion or a BirA biotine ligase fused in frame to any antibiotic resistance gene in a way that does not interfere with its ability to biotinylate the Avi-tag, no further use of fluorescent or selection marker is required.
  • Non limitative examples are: the Lacl repressor of the Lac Switch system (Stratagene), the modified ecdysome receptor of the GAL4-DBD/hPR-LBD/p65-AD regulatory fusion protein of the GeneSwitchTM System (Life technologies), the pFB-ERV vectors (stratagene), the SparQTM Cumate Switch system from system biosciences, etc..
  • infection and/or selection of the appropriate cell population can occur sequentially or in parallel depending on the fluorescent or selection markers used as appreciated by those skilled in the art.
  • the present invention provides the use of a reporter molecule for determining the activation status of endogenous CDK4, wherein said reporter molecule comprises a cyclin D/cyclin-dependent-kinase 4 (CDK4) fusion protein.
  • the reporter molecule may further comprise an affinity tag.
  • the present invention relates to a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract, said kit comprising a eukaryotic cell line and a cyclin D/CDK4 fusion protein.
  • the CDK4 part of the fusion protein may be in the hyperphosphorylated form.
  • the CDK4 part of the fusion protein may be in the hypophosphorylated form.
  • the present invention relates to a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract, said kit comprising a eukaryotic cell line and a nucleic acid encoding a cyclin D/CDK4 fusion protein.
  • the genomic material of said eukaryotic cell line may comprise said nucleic acid encoding the cyclin D/CDK4 fusion protein.
  • the kit may comprise an expression vector comprising the nucleic acid encoding a cyclin D/CDK4 fusion protein.
  • kits may be configured for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract.
  • a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract said kit comprising a eukaryotic cell line and a cyclin D/CDK4 fusion protein.
  • a kit for determining the activation status of endogenous CDK4 in eukaryotic cells or a eukaryotic cell extract said kit comprising a eukaryotic cell line and a nucleic acid encoding a cyclin D/CDK4 fusion protein.
  • Non-limiting examples of the reporter molecule and reporter system according to different embodiments of the present invention are for instance illustrated in Figures 1 and 2.
  • a reporter system comprising a reporter molecule according to an embodiment of the present invention and the biotine ligase (BirA) protein.
  • the reporter molecule according to an embodiment of the present invention comprises a cyclin D/CDK4 fusion protein, an Avi tag, a tobacco etch virus 1 cleavage site (TEV), enhanced green fluorescent protein (EGFP), and the SB1 epitope (SBI epi).
  • the construct expressing the reporter system according to an embodiment of the present invention is shown below in Figure 1 .
  • the reporter molecule is expressed under the control of a tet response element.
  • Each reporter system illustrating the present invention comprises a reporter molecule according to an embodiment of the present invention and a BirA protein bound to the Avi tag.
  • the reporter molecules illustrating the present invention comprise a cyclin D/CDK4 fusion protein, an Avi Tag and one or more tags selected from enhanced green fluorescent protein (EGFP), Flag, V5, Myc, HA, SB1 epitopes (SBI epi), glutathion- S-transferase (GST), SNAP/CLIP tag and Halo tag.
  • any other tag or epitope may be used as an affinity tag such as a STREP tag, maltose binding protein (MBP), poly-histidine tag, etc.
  • MBP maltose binding protein
  • the Avi-tag may be located at the C-terminus of the cyclin D/CDK4 fusion protein or the Avi-tag may be located in the construct at the C-terminus of the transgene for instance with two copies of the SB1 epitope located in front of the TEV cleavage sites as show in the upper panel of Figure 2.
  • reporter molecules as illustrated in Figure 2 comprise the TEV tobacco etch virus cleavage site (TEV).
  • TEV tobacco etch virus cleavage site
  • Other consensus cleavage sites or inteins can replace the TEV sequence as appreciated by those skilled in the art.
  • binding molecule refers to all suitable binding molecules that are specifically binding or interacting with phosphorylated CDK4 as defined by the present invention.
  • suitable binding agents are antibodies, monoclonal- or polyclonal antibodies, nanobodies, affybodies, antibody fragments, antigen binding fragments of antibodies, aptamers, photoaptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers,
  • Both monoclonal, polyclonal or single chain antibodies or antigen-binding antibody fragments that specifically bind the phosphorylated form of CDK4 are useful in the methods and kits of the present invention.
  • Monoclonal and polyclonal antibodies or their antigen-binding fragments can be prepared by methods known in the art and are often commercially available. Aptamers that bind specifically to the phosphorylated form of CDK4 can be obtained using the so called SELEX or Systematic Evolution of Ligands by Exponential enrichment. In this system, multiple rounds of selection and amplification can be used to select for DNA or RNA molecules with high specificity for a target of choice, developed by Larry Gold and coworkers and described in US patent 6,329,145.
  • the invention hence further provides assays, tools and methods for the identification of such phospho-CDK4-specific binding molecules, such as peptides or small molecules, monoclonal- or polyclonal antibodies, nanobodies, affybodies, antigen- binding antibody fragments, aptamers, photoaptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers, aptamers,
  • the invention provides the use of cells and/or cell-lines that are transfected with the cyclin D/CDK4 fusion proteins according to the invention for identifying binding molecules that specifically bind the phosphorylated form of CDK4.
  • the invention provides the use of the cyclin D/CDK4 fusion proteins according to the invention for identifying binding molecules that specifically bind the phosphorylated form of CDK4.
  • the invention provides for a method of identifying binding agents that are specific for the phosphorylated form of CDK4, comprising the steps of comparing the binding affinity of said binding molecules to the phosphorylated fusion Cyclin D/CDK4 fusion protein, wherein said fusion protein can be phosphorylated in vitro or in vivo.
  • the cyclin D/CDK4 fusion protein is contacted with a cell extract or either serum-activated cells or quiescent cells, and the binding of the candidate binding agent is compared in both cases.
  • Higher binding affinity towards the serum- activated fusion protein indicates specificity for the phosphorylated form of CDK4.
  • the binding molecule would have no or very low affinity for the non-phosphorylated CDK4 (i.e. contacted with extract of quiescent cells) and high affinity for the phosphorylated CDK4 (i.e. the fusion protein contacted with serum-activated cell extract). Since the fusion proteins according to the present invention can be immobilized on a suitable matrix, detection and even purification of the specific binding molecules is simplified.
  • the in vivo assay or method cells are used that were stably transfected with the fusion proteins according to the present invention.
  • the fusion protein can be extracted from these cells through the affinity tags in the plasmids. Comparing the binding affinity towards the isolated fusion proteins obtained from cultures of cells that were treated with serum or were left quiescent will again enable the identification and characterization of those binding molecules that are specific for the phosphorylated CDK4 isoform.
  • said kits can also comprise the neessecary means to activate cells or to leave them in a quiescent state.
  • Example 1 Assays to determine the activation status of CDK4
  • a first configuration of an assay according to an embodiment of the present invention (illustrated in Figure 3 and in the left panel of Figure 4), phosphorylation of the CDK4 part of the cyclin D/CDK4 fusion protein occurs in intact cells, transfected with a nucleic acid encoding a reporter molecule comprising the cyclin D/CDK4 fusion protein.
  • phosphorylation of the CDK4 part of the cyclin D/CDK4 fusion protein occurs in vitro, in particular in cellular extract.
  • the cyclin D/CDK4 fusion isolated in a hypo-phosphorylated state from quiescent MCF7 cells stably expressing the cyclin D/CDK4 fusion is immobilized on streptavidin- coated matrix.
  • the cyclin D/CDK4 fusion can be isolated from HEK293T cells transiently transfected with an expression vector for the cyclin D/CDK4 fusion or from proliferating MCF7 cells stably expressing the cyclin D/CDK4 fusion, immobilized on streptavidin-coated matrix and dephosphorylated by a phosphatase such as, for example, the ⁇ -phosphatase.
  • the immobilized hypophosphorylated cyclin D/CDK4 fusion protein is incubated with cellular extracts or purified kinases together with ATP and optionally molecules under investigation before the Rb kinase activity of the immobilized cyclin D/CDK4 fusion protein, or its activation state will be measured as described herein.
  • Cellular extract will be prepared from cells overexpressing specific kinases or in which expression of a specific kinase had previously been decreased by siRNA or with any other suitable technology known to those skilled in the art.
  • the choice between the two assay configurations will be dictated by the compatibility between the time course of the regulation of the CDK4 phosphorylation and the time course of the tested biological perturbation, e.g. siRNA transfection, kinase overexpression, or addition of a chemical compound.
  • Example 2 Screening of siRNA library to identify CDK4 activating kinases
  • the assay or method is based on an in vivo regulation of phosphorylation of CDK4.
  • the assay is based on the generation of stable eukaryotic cell lines using retrovirus.
  • Retroviruses can insert a plasmid construct into the genome of the eukaryotic cells.
  • a siRNA directed against a target activating kinase for instance a proline directed kinase (PDK) is introduced into the eukaryotic cells upon inducing proliferation of the eukaryotic cells.
  • PDK proline directed kinase
  • the reporter molecule is isolated from the eukaryotic cells and the activation status of CDK4 measured using for instance the DELFIA system.
  • the assay or method is based on an in vitro regulation of phosphorylation of CDK4.
  • the plasmid constructs is transiently transfected in HEK293T cells.
  • the cyclin D/CDK4 fusion protein is extracted and purified on wells covered with streptavidin.
  • a siRNA directed against a target activating kinase for instance a proline directed kinase (PDK)
  • PDK proline directed kinase
  • the protein lysate of this eukaryotic cell line is recovered and brought onto the reporter molecule comprising the cyclin D/CDK4 fusion protein.
  • the activation status of CDK4 is then measured for instance with the DELFIA system.
  • Example 3 Screening of inhibitory compounds of cyclinD/CDK4 complexes to identify anti-cancer drugs or drugs effective against proliferative diseases
  • a reporter molecule comprising a cyclin D/CDK4 fusion protein is produced in a eukaryotic cell line by culturing the cells while they are kept in a quiescent state, thereby producing the cyclin D/CDK4 fusion protein wherein CDK4 is present in a hypophosphorylated form. Subsequently, a compound of interest is added to the eukaryotic cells upon inducing proliferation of the eukaryotic cells. Next, the reporter molecule is isolated from the eukaryotic cells and the activation status of CDK4 measured using for instance the DELFIA system.
  • the compound is an inhibitory compound of the upstream pathway of the cyclin D/CDK4 complex, for instance if the compound is directed against a CDK4 activating kinase or blocks cyclin D/CDK4 phosphorylation, no substrate phosphorylation is present in the wells.
  • Example 4 Comparison of the reporter molecule comprising a cyclin D3/CDK4 fusion protein with other reporter molecules
  • Example 5 Measurement of the activation status of CDK4 with anti-phospho-CDK4 or anti-phospho-TP antibodies or with nanobodies
  • Direct quantification of CDK4 phosphorylation is performed with anti-phospho-CDK4 or anti-phospho-TP antibodies or with nanobodies selected to recognize specifically either the non-phosphorylated or the phosphorylated state of the CDK4.
  • the Avi-tag is initially located at the C-terminus of the fusion proteins as described in (Schaffer et al., supra). Another set of constructs with the Avi-tag located after the CDK4 sequence in front of a TEV cleavage site placed before an EGFP or a GST sequence is generated.
  • biotinylation of the Avi-tag located within the fusion protein is as efficient as the biotinylation of the Avi-tag located at the C-terminus of the fusion, tandem purification of the cyclin D/CDK4 fusions is possible.
  • the biotinylated Avi-tagged cyclin D/CDK4 moiety of the fusion proteins will be released by digestion with the TEV protease.
  • both cyclin D and biotinylated avi-tagged CDK4 part could be further dissociated by treatment with the Prescission protease.
  • the biotinylated CDK4 fragment of the cyclin D/CDK4 fusion protein will be bound to streptavidin immobilized on a solid matrix. Phosphorylation of this peptide can be detected by anti-phospho-CDK4 or anti-phospho-TP antibodies or with nanobodies or aptamers.
  • the phosphorylation status of tryptic fragments of the CDK4 fragment of the cyclin D/CDK4 fusion proteins immobilized on streptavidin can be quantified directly by mass spectrometry.
  • the activating phosphorylation of CDK2 induces a dramatic change in its conformation.
  • the impact of the T172 phosphorylation on the conformation of CDK4 is less severe and not as well characterized.
  • Binding of ATP, ATP analogues, appropriately designed pseudo-substrates, or modified p21 or p27 proteins is determined according to the phosphorylation status of the cyclin D/CDK4 fusion protein.
  • the composition of isolated cyclin D/CDK4 fusion protein complexes is compared between quiescent and serum stimulated cells at different times of the cell cycle.
  • Comparative mass spectrometry methods such as SILAC or COFRADIC, or comparative 2D gel electrophoresis methods such as 2D-DIGE, or other techniques known to those skilled in the art such as derivatives of two hybrid technologies, can be used in this matter.
  • a phosphorylation state- specific interaction partner of the cyclin D/CDK4 fusions is identified, its interaction domain is determined and fused to reporter proteins such as luciferase, peroxidises, or fluorescent proteins to quantify its binding to the cyclin D/CDK4 fusion protein. Binding of the phosphorylation state-specific interaction partner of the cyclin D/CDK4 fusion protein can also be quantitated using specific antibodies, nanobodies or aptamers.
  • FIG. 3 A preferred setup of the assay is depicted in Figure 3.
  • a reporter molecule is stably incorporated in the genome of a mammalian cell model suitable to follow the CDK4 activation such as MCF7 cells.
  • This reporter molecule can be under the control of a constitutive promoter or inducible promoter.
  • Figure 3 illustrates the situation where the transgene expression is driven by a Tet On system. When cells express the Tet activator, addition of doxycyclin to the cells induces a conformational change in the Tet regulator which is then able to bind to a specific sequence added in front of the transgene expression module. This binding activates transcription of the reporter molecule ( Figure 3, step 1 ).
  • This reporter molecule comprises the sequence of a cyclin D/CDK4 fusion protein linked to an Avi tag.
  • the Avi tag encodes for a consensus peptide of 13 amino acids recognized by the biotin ligase of E. Coli and biotinylated by this enzyme ( Figure 3, step 2).
  • the BirA enzyme is expressed together with the fusion protein via an IRES sequence cloned between the nucleic acid sequence encoding the fusion protein and the nucleic acid sequence encoding the BirA biotin ligase.
  • the IRES sequence when present in a mRNA can bind to ribosomes and allows them to start translation at this site, albeit with a low efficiency.
  • constitutive or inducible expression of the BirA biotin ligase can be supported by another locus.
  • the Avi tag coupled to the cyclin D/CDK4 fusion protein may be followed by two TEV cleavage sites recognized and cut by the TEV protease.
  • the TEV sites may be coupled to an EGFP sequence to allow easy identification and tracing of cells expressing the transgene.
  • the EGFP sequence may be used to purify the transgene on Protein-A sepharose beads loaded with an anti-EGFP antibody.
  • the EGFP sequence may be followed at its C- terminus by an SB1 epitope which can be recognized by a specific monoclonal antibody.
  • the SB1 epitope can eventually be used to purify the transgene on Protein-A sepharose beads loaded with an anti-SB1 antibody as described previously (Schaffer et al., supra).
  • the Avi-tag may be located in the construct at the C-terminus of the transgene while two copies of the SB1 epitope are located in front of the TEV cleavage site as show in Figure 2, upper panel.
  • the SB1 epitope can eventually be used to purify the transgene on Protein-A sepharose beads loaded with an anti-SB1 antibody as described previously (Schaffer et al., supra).
  • the Avi-tag may be located in the construct at the C-terminus of the transgene while two copies of the SB1 epitope are located in front of the TEV cleavage site as show in Figure 2, upper panel.
  • the SB1 epitope can be replaced by an other purification tag as known to those skilled in the art as examplified in Figure 2.
  • Cells expressing the cyclin D/CDK4 fusion protein tagged with the Avi-tag and expressing the BirA biotin ligase are then induced to proliferate while specific genes (especially proline-directed kinases) are overexpressed or knocked down by siRNA silencing or any other methods known to those skilled in the art (Figure 3, step 2).
  • Proliferation can also be induced together with treatment of the cells with chemicals under investigation ( Figure 3, step 2). At the end of these treatments, cells are lysed in non denaturing condition ( Figure 3, step 3) before the fusion proteins are purified by the appropriate purification technique.
  • fusion proteins are first purified on a protein-A sepharose matrix loaded with anti-SB1 antibody and eventually released by cleavage with the TEV protease (Figure 3, step 4).
  • the cyclinD/CDK4 fusion protein can then be purified on immobilized streptavidin before further analysis by mass spectroscopy ( Figure 3, step 5), Rb kinase assay ( Figure 3, step 6), or immunodetection with the Delfia technology ( Figure 3, step 7), or other methods known to those skilled in the art.
  • the cyclin D and the CDK4 moieties of the cyclin D/CDK4 fusion protein can be separated by a linker including a protease sensitive cleavage site. Proteolytic dissociation of the cyclin D/CDK4 fusion protein followed by thermic denaturation of the lysate will allow specific purification of the CDK4 moiety by immobilized streptavidin. The phosphorylation status of this peptide can subsequently be determined using any anti-phospho-CDK4 or any phospho-TP antibody as well as by mass spectroscopy or any other relevant technique known to those skilled in the art.
  • Presence of the anti-phospho-CDK4 or the phospho-TP antibody on the immobilized CDK4 part of the fusion could be detected by the DELFIA technology as illustrated in Figure 3, or by radioactive, colorimetric or chemiluminescence methods known to those skilled in the art.
  • Example 8 Generation of lentiviral expression vectors to record the activation of CDK4 upon induction of proliferation
  • a lentiviral expression system was generated to express transgenes marked with a biotinylable tag, the Avi tag.
  • the Avi tag allows easy purification of the proteins to which it is coupled to by streptavindin coupled supports as described previously (Schaffer et al., 2009, Nucleic acid res., 38, 1 -13).
  • Table 2 Plasmids used in the construction of the reporter molecule as used in the assay according to an embodiment of the present invention and plasmids used in the construction of control constructs
  • the pDLVCTEGFPTetOV5HisLuc vector used as positive control for non-biotinylable luciferase was obtained at the University of Ghent by recombination of the pDLVCTEGFPTetOV5His destination vector with the pENTRDTopo-Luc using the LR clonase mix of Invitrogen according to the instruction of the manufacturer.
  • the former is a derivative of the pWPI vector (Addgene # 12254) described by the team of Pr. Trono (University of Lausanne, Switzerland) (Wiznerovicz et al., 2003, J. Virol., 77, 8957-8961 ) in which an expression module 1 (SEQ ID NO.
  • the expression module comprised a tet response element followed by the CMV promoter in front of a Gateway recombination module coupled in frame to a V5His tag and an internal ribosome entry site (IRES) sequence driving the expression of the fluorescent protein EGFP.
  • the Luciferase entry vector pENTRDTopo-Luc was created at the University of Ghent by amplifying the luciferase reporter gene from the pGL4 plasmid (Promega) by PCR and cloning the corresponding fragment in the pENTRDTopo vector.
  • the inventors transferred the EGFP-Avi tag together with a Gateway recombination module from the vector pBY2807 acquired via Addgene (Addgene plasmid #23222) described previously (Schaffer et al., supra) in the vector pLVTH/KrabRed (Addgene plasmid #1 1643) described by the team of Pr. Trono (University of Lausanne, Switzerland) (Wiznerovicz et al., supra).
  • tet response element followed by the EF1 oc promoter in front of a Gateway recombination module and an internal ribosome entry site (IRES) sequence driving the expression of the BirA/mCherry fusion excised from the pBY2982 plasmid acquired via Addgene (Addgene plasmid #23220) described previously (Schaffer et al., supra).
  • This module i.e., expression module 2 (SEQ ID NO. 20), was inserted between the PpuMI and Ndel sites of the pLVTH/KrabRed vector to create the destination vector pWFAvilBc.
  • Another module i.e., expression module 3 (SEQ ID NO.
  • the BirA puromycin resitance gene fusion was obtained by combining the BirA sequence of the pBY2982 plasmid and the puromycin resitance gene through a Ncol site.
  • numerous strategies involving PCR or not can be followed to achieve these constructs according to protocols well known in the field.
  • Recombinant DNA was transformed in DB3.1 bacteria. Clones transformed with the expected plasmid were selected according to the restriction profile obtained after the digestion of their plasmid DNA with Ncol.
  • the inventors transferred the BirA coding sequence of the pBY2982 plasmid acquired via Addgene (Addgene plasmid #23220) described previously (Schaffer et al., supra) to the the vector pLVTH/KrabRed (Addgene plasmid #1 1643) described by the team of Pr. Trono (University of Lausanne, Switzerland) (Wiznerovicz et al., supra) by digesting the former with Smal and MscI and inserting the BirA coding fragment in the latter cut by Smal and Pmel.
  • the DsRED selection marker of the resulting plasmid was further replaced by a neomycin resistance gene through its Kpnl/Kpnl digestion and ligation with a Kpnl/Kpnl DNA fragment isolated from the pLVINeo plasmid.
  • This plasmid was obtained by transfering the IRES sequence followed by the Neomycin resistance gene cut by BamHI/Xbal from the pIRESNeo plasmid from Clontech (Genbank #1189673) in the pLVET-tTR-KRAB vector (Addgene plasmid #1 1644) described by the team of Pr. Trono (University of Lausanne, Switzerland) (Wiznerovicz et al., supra) cut by BamHI and Spel.
  • the inventor also created a lentiviral vector to express the rTTA3 doxycyclin-sensitive regulator under the control of the strong EF1 oc eukaryotic promoter together with the DsRED fluorescence marker under the control of and IRES sequence.
  • the pDG2iV5puro vector created at the University of Ghent and described previously was first cut by Xbal and re-ligated.
  • the puromycin selection marker from this plasmid was then replaced by a DsRED selection marker through its Kpnl/Kpnl digestion and ligation with a Kpnl/Kpnl DNA fragment isolated from the pLVTH/KrabRed plasmid (Addgene plasmid #1 1643) to create the pDG2rTTA3IDR plasmid.
  • the rTTA3 regulator was finally inserted downstream of the EF1 oc promoter by transferring the Mlul/Spel fragment of the pDG2rTTA3IDR plasmid including the rTTA3 regulator in the the pLVTH/KrabRed plasmid (Addgene plasmid #1 1643) cut by Mlul and Spel to generate the vector pl_VrTTA3IDRm (SEQ ID No. 67).
  • the inventors generated a lentiviral expression vector called pWNV5His allowing the induction by doxycyclin of the expression of a transgene fused to the V5His tag by inserting a Ppuml/Xmal fragment of the pDG2iV5puro vector created at the University of Ghent and described previously (Bisteau et al, PLoS Genet. 2013 May;9(5):e1003546) into the Ppuml/Xmal-cut pDLVCTEGFPTetOV5His vector described above.
  • the inventors also generated lentiviral expression vectors allowing the induction by doxycyclin of the expression of a fusion protein containing the Avi-tag separated from a poly-histidine purification tag by two TEV cleavage sites and eventually a GFP sequence.
  • the vector including the Avi-tag, the TEV sites, the GFP sequence and the poly-histidine purification tag was generated first by PCR amplification of part of the Gateway cassette from the vector pDLVCTEGFPTetOV5His described above with the primers ESR46 and ESR47 described below. Next the GFP sequence preceded by TEV sites was amplified by PCR from the pWFAvilBc DNA with the primers ESR50 and ESR51 described below.
  • the combined Avi-tag and TEV sites sequences were generated by annealing the ESR49 and ESR48 primers and extending the annealed DNA by PCR amplification.
  • the Gateway cassette amplicon was combined with the resulting Avi-tag-TEV sequence and amplified by PCR with the primers ESR46 and ESR49.
  • the TEV-GFP amplicon was combined with the resulting Avi-tag-TEV sequence and amplified by PCR with the primers ESR48 and ESR51 .
  • These two amplicons were combined with the pWNV5His vector cut with Mlul and Xmal using the Gibson assembly Mix (NEB) to create the pWNATGHis vector.
  • the pWNATHis vector lacking the GFP sequence between the TEV sites and the poly- histidine tag was created by amplifying the Gateway cassette fragment followed by the Avi-tag and two TEV sites from the pWNATGHis vector with the primers ESR46 and ESR52 and combining the corresponding amplicon with the pWNV5His vector cut with Mlul and Xmal using the Gibson assembly Mix (NEB).
  • pWFAvilBc, pWFAvilBp, pWNATGHis and pWNATHis were recombined with entry vectors (pENTRtopo vectors) comprising the expression modules for luciferase (pENTRtopo_Luc), cyclin D1 (pENTRtopo_D1 ), CDK4 (pENTRtopo_K4), cyclin D1/CDK4 fusion protein (pENTRtopo_D3LxK4, with x being 1 , 2 or 3 depending on the linker used), or cyclin D3/CDK4 fusion protein (pENTRtopo_D3LxK4, with x being 1 , 2 or 3 depending on the linker used) using the LR clonase mix of Invitrogen according to the instruction of the manufacturer (Gateway system recombination).
  • entry vectors comprising the expression modules for luciferase (pENTRtopo_Luc), cyclin D1 (pENTRtopo_D1
  • Recombinant DNA was transformed in Top10 bacteria.
  • Clones transformed with the expected plasmid were selected according to the restriction profile obtained after the digestion of their plasmid DNA with Ncol.
  • Complete sequences of the resulting plasmids can be found in the sequence listing: pWNATGHisJ-UC (SEQ ID No. 69); pWNATGHis_D3L3K4 (SEQ ID No. 68); pWNATHisJ-UC (SEQ ID No. 71 ); pWNATHis_D3L3K4 (SEQ ID No. 70).
  • the sequence Linker 3 (L3) can be found in SEQ ID No. 72 (DNA) and 73 (amino acid).
  • Entry vectors for cyclin D1 , CDK4, cyclin D1/CDK4 fusion protein or cyclin D3/CDK4 fusion protein were created by amplifying the corresponding sequences with the PFX polymerase and cloning the respective inserts in the pENTRDTopo vector according to the instruction of the manufacturer (Invitrogen). Fusion protein entry vectors were created by a multistep PCR strategy. Both the cyclin D with a part of the linker and the CDK4 with a part of the linker partially overlapping the former were separately amplified by PCR. The PCR products were next mixed in a new PCR reaction including the cyclin D forward primer and the CDK4 reverse primer. The sequences of the primers used to this end are described in Table 3.
  • the PCR primers and conditions used to generate the different inserts are given in Tables 4 and 5 respectively.
  • the PCR reaction mix included 5 ⁇ PFX Buffer, 5 ⁇ PFX Enhancer Buffer, 1.5 ⁇ dNTP Mix (10 mM for each), 1 ⁇ MgS0 4 50 mM, 1 ⁇ Primer 1 (Table 4), 1 ⁇ Primer 2 (Table 4), 1 ⁇ Primer 3 (Table 4, when indicated), all at 200 ng/ ⁇ , 1 ⁇ of DNA template 1 (Table 5), 1 ⁇ DNA template 2 (Table 5, when indicated) both at 100 ng/ ⁇ , 1 ⁇ PFX polymerase brought to a final volume of 50 ⁇ with autoclaved ultapure DNAse-free water.
  • Amplification was started by incubating the PCR mix for 2 minutes at 94°C. This incubation was followed with 30 cycles of incubation at 94 °C for 15 seconds, incubation at the indicated temperature (Table 5, hybridization temperature) for 30 seconds, and for the indicated time (Table 5, elongation time) at 68 °C. The PCR reaction was ended by incubation for 7 minutes at 68 °C and stored afterwards at 4 °C.
  • Entry vectors including the non-activable T172A mutant of CDK4 were generated by site- directed mutagenesis of the corresponding wild type constructs using the QuikChange mutagenesis kit (Stratagene) and the primers 4153CDK4T172A_QC_F (SEQ ID No. 76) and 4153CDK4T172A_QC_R (SEQ ID No. 77).
  • Table 3 Sequences of primers used for the amplification of cyclin D1 , CDK4, cyclin D1/CDK4 fusion protein, and cyclin D3/CDK4 fusion protein
  • Example 9 MCF7 cells rendered quiescent and stimulated to grow by serum and insulin
  • MCF7 cells (ATCC HTB-22) were routinely cultivated in Dulbecco's Modified Eagle Medium (DMEM) comprising 5% serum, 6 ng/ml insulin, 0.1 mM non essential amino acids (NEAA, GIBCO), 1 mM Sodium pyruvate, 50 U/ml Penicillin and 50 pg/ml Streptomycin.
  • DMEM Dulbecco's Modified Eagle Medium
  • NEAA non essential amino acids
  • GIBCO non essential amino acids
  • the cells were rendered quiescent by incubating them for three days in phenol-free DMEM without serum and insulin, but supplemented with 0.1 mM NEAA (GIBCO), 1 mM Sodium pyruvate, 50 U/ml Penicillin and 50 ⁇ g/ml Streptomycin.
  • Example 10 Induction of MCF7 cell proliferation associated with time-dependent changes in cyclin protein expression levels and Rb phosphorylation
  • MCF7 cells were cultivated and rendered quiescent as described in Example 9. Subsequently, MCF7 cells were kept quiescent or stimulated to proliferate as described in Example 9 for 2h, 4h, 6h, 8h, 10h, 12h, 16h, 24h, 28h, and 32h. At the indicated times, cells were washed with PBS, scraped in 200 ⁇ of denaturing lysis Laemmli buffer (glycerol 5 %, 30 mM Tris-HCI (pH 6.8), 1 % SDS, 50 mM DTT, 25 mM NaF, 50 ⁇ vanadate, and protease inhibitors), boiled for 5 min, and frozen. Proteins were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride (PVDF) membranes (Perkin Elmer).
  • SDS-PAGE sodium dodecyl sulfate-
  • Membranes were probed using the H-22 polyclonal CDK4 antibody (Santa Cruz, Rabbit), the DCS-6 mouse monoclonal anti-cyclin D1 antibody (Neomarkers), the DCS-22 mouse monoclonal anti-cyclin D3 antibody, the E72 anti-cyclin A mouse monoclonal antibody (Neomarkers), the GNS1 anti-cyclin B mouse monoclonal antibody (Neomarkers), and the HE12 anti-cyclin E mouse monoclonal antibody (Thermo Fisher), antibody.
  • Anti-rabbit immunoglobulin antibody or anti-mouse immunoglobulin antibody were used for detection by enhanced chemiluminescence (Western Lightning, Perkin-Elmer, Boston, MA). Various exposures of the bands corresponding to these proteins were collected on Hyperfilms (GE Healthcare).
  • Rb phosphorylation is recognized by the upward shift of the apparent molecular weight of the Rb protein detected with the anti-Rb and anti-phospho Rb antibodies used by double immunofluorescent detection using the Odyssey infrared fluorescence scanner (LI-COR).
  • induction of proliferation is associated with a time-dependent increase in the expression of various cyclins.
  • G1 cyclins such as cyclin D1 and cyclin D3 started early after serum exposure, while the induction of G2 cyclins such as cyclin A and cyclin B was delayed.
  • Phosphorylation of the Rb protein was also stimulated by serum addition. Phosphorylation of the Rb protein started 10h after stimulation and was maximal 24 h after stimulation.
  • Example 11 Induction of MCF7 cell proliferation was associated with an increase in endogeneous CDK4 phosphorylation on T172.
  • MCF7 cells were cultivated and rendered quiescent as described in Example 9. Subsequently, MCF7 cells were kept quiescent (control) or stimulated to proliferate (serum) for the indicated times as described in Example 9. At the indicated times, cells were washed with PBS, lysed on ice in 1 ml NP-40 lysis buffer.
  • the homogenized (glass/glass) cellular lysate was sonicated 3 times, precleared for 30 minutes with protein A-Sepharose (GE Healthcare, Uppsala, Sweden), and then incubated at 4°C for 3 h with protein A-Sepharose which had been pre-incubated overnight with 3 ⁇ g of monoclonal antibodies against cyclin D1 (DCS-1 1 ) or cyclin D3 (DCS-28) (all from Neomarkers, Fremont, CA).
  • Immunoprecipitated proteins were denatured in a buffer comprising 7 M urea, 2 M thiourea, 4% CHAPS, 1 % DTE, 1 % Pharmalytes 3-10 (GE Healthcare) and 1 mg/ml pefablock before being resolved by 2D gel electrophoresis separations. Proteins were separated by isoelectric focusing using the Protean IEF cell apparatus from Bio-Rad after active in-gel rehydration on immobilized linear pH gradient (pH 3 to 10) strips (GE Healthcare). After loading onto SDS-polyacrylamide slab gels (12.5%) for separation according to molecular mass, proteins were transferred to PVDF membranes (Perkin Elmer).
  • CDK4 was immunodetected using the H-22 polyclonal antibody (Santa Cruz).
  • the Rb-kinase assay was performed on cyclin D1/CDK4 or cyclin D3/CDK4 complexes immunoprecipitated from cellular extracts of MCF7 quiescent cells treated or not for the indicated time with serum as described previously (Coulonval et al., 2003, Exp. Cell Res., 291 , 135-149).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.5 ⁇ g of a 48- kDa fragment (amino acid 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with gentle agitation.
  • HEK293T cells (ATCC CRL 1 1268) were transiently transfected with the corresponding DNA produced with the Qiagen midiprep kit following the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (Invitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 g/ml) and 10% foetal calf serum. 6 10 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method.
  • plasmids ( ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours.
  • Tris buffer Tris 50mM; EDTA 1 mM
  • Anti-rabbit immunoglobulin antibody or anti- mouse immunoglobulin antibody were used for detection by enhanced chemiluminescence (Western Lightning, Perkin-Elmer, Boston, MA). Various exposures of the bands corresponding to these proteins were collected on Hyperfilms (GE Healthcare).
  • Example 13 Immobilization on streptavin -coated sepharose beads of transgenes expressed after transient transfection in HEK293T cells and assay for their activity
  • HEK293T cells were cultivated and transfected with the indicated plasmids as described in Example 12.
  • the inert plasmid pBluescript was used as negative transfection control (noted CT) in the experiments shown in Figure 8.
  • luciferase assay For the luciferase assay, cellular extracts were diluted to a final volume of 200 ⁇ . Input luciferase activity was assessed in two 20 ⁇ samples of the bead suspension after the 3 hour incubation. Two 20 ⁇ samples of the bead supernatant recovered after the first centrifugation of the beads were spotted in a black 96 well plate for luciferase assay
  • the pRb kinase assay was performed on the cellular extract bound to the streptavidin- 25 coated sepharose beads as described previously (Coulonval et al., 2003, Exp. Cell Res., 291 , 135-149). After 3 hours of incubation at 4°C with streptavidin-coated sepharose beads, complexes were washed three times with 0.5% NP-40 lysis buffer supplemented with 1 mM DTT and three times with kinase reaction buffer (50 mM Hepes, pH 7.5, 10 mM KCI, 10 mM MgCI2, 2.5 mM EGTA, 1 mM DTT).
  • Washed complexes were resuspended in 30 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.5 ⁇ g of a 48-kDa fragment (amino acid 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice- concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM 35 DTT, 50 mM NaF, 100 ⁇ vanadate, and protease inhibitors) and boiling for 5 min.
  • twice- concentrated Laemmli buffer glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM 35 DTT, 50 mM NaF, 100 ⁇ vanadate, and protease inhibitors
  • Proteins were resolved by SDS-PAGE and transferred on PVDF membranes (Perkin Elmer) before the phosphorylation on T826 of the pRb fragment was detected using the phosphor-specific pRb (T826) antibody (Thermo Fisher). Membranes were then reprobed using the H-22 polyclonal CDK4 antibody (Santa Cruz, Rabbit). An anti-rabbit or anti- mouse immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase was used for detection by enhanced chemiluminescence (Western Lightning; Perkin-Elmer, Boston, MA).
  • Figure 9A shows that up to 40 % of the total luciferase activity was bound to the streptavidin-coated sepharose beads in cellular extract of HEK293T cells transfected with an expression vector of an Avi-tagged luciferase. No luciferase activity was detected when the cells were transfected with vector allowing the expression of a cyclinD/CDK4 fusion protein. By contrast, Rb kinase activity was only bound to beads incubated with extracts of HEK293T cells transfected with vectors allowing the expression of a cyclinD/CDK4 fusion protein. Both cyclin D1/CDK4 and cyclin D3/CDK4 fusion proteins were active ( Figure 9B).
  • Example 14 Transgenes were expressed and biotinylated in stable cell populations of MCF7 cells transduced with lentiviruses allowing the expression of Avi-tagged transgenes and a BirA mCherry fusion protein
  • Lentiviruses were produced by co-transfecting HEK293T cells with 3 ⁇ g of the lentiviral vectors constructed as described in Example 8 and 1 .5 and 3 ⁇ g of the packaging vectors pMD2.G and pCMVAR8.2, respectively.
  • pMD2.G Additional plasmid #12259
  • pCMVAR8.2 Additional plasmid #12263
  • plasmids were described previously by Pr. Trono's team (University of Lausanne, Switzerland) (Wiznerovicz et al., supra). To this end, these plasmids were first precipitated together with sodium acetate and resuspended in 10 ⁇ of ultrapure DNAse-free water.
  • the DNA mixture was added to 190 ⁇ of Tris buffer (Tris 50mM ; EDTA 1 mM) and 50 ⁇ of 2.5M CaCI 2 . This solution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 .5mM). After incubation for 10 min at 37°C, 250 ⁇ of the mixture was added on 6.10 5 HEK293T cells seeded in two wells of a 6-well plate per construct, the day before transfection (2.5 ml of medium/well).
  • Tris buffer Tris 50mM ; EDTA 1 mM
  • 2.5M CaCI 2 2.5M
  • Chloroquine 25 ⁇ was added in each well before incubation at 36 °C for 6 hours. Thereafter, the medium was refreshed and cells were incubated at 36 °C in 2.5 ml HEK293T cell culture medium per well. After 48 hours, the virus-containing medium was harvested and filtered through a 0.45-mm low protein-binding filter (Millipore, Billerica, MA, USA). Aliquots were stored at - 70°C. Transduction of MCF7 cells or MCF7/KR cells done in triplicate, was performed by mixing 10 4 cells with 200 ⁇ viral supernatant in a 96-well plate.
  • MCF7/KR cells are MCF7 cells expressing the Tet KRAB repressor after transduction with the pLVTH/KR plasmid (Addgene plasmid #12249) described by the team of Pr. Trono (University of Lausanne, Switzerland) (Wiznerovicz et al., supra).
  • Anti- rabbit immunoglobulin antibody (GE Healthcare) or anti-mouse immunoglobulin antibody (GE Healthcare), both coupled to horseradish peroxidase were used for detection by enhanced chemiluminescence (Western Lightning, Perkin-Elmer, Boston, MA).
  • Example 15 Purified immobilized biotinylated Avi-tagged Cyclin D3/CDK4 fusion expressed in stable cell populations of MCF7 cells displayed a Rb-kinase activity modulated according to their proliferation status
  • the MCF7 cells expressing the luciferase or the cyclin D3/CDK4 fusion protein described in the Example 14 were cultivated in 10 cm Petri dishes 5 with 10 ml DMEM medium supplemented with 5% serum, insulin 6 ng/ml, NEAA (Gibco) 0.1 mM, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml).
  • the cells were rendered quiescent by incubating them for three days in phenol-free DMEM without serum and insulin, but supplemented with biotin (0.1 mM), NEAA (0.1 mM, Gibco), Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml). During the last
  • fulvestrant 10 nM was added to the culture to block estrogen receptor action.
  • luciferase assay For the luciferase assay, cellular extracts were diluted to a final volume of 200 ⁇ . Input luciferase activity was assessed in two 20 ⁇ samples of the bead suspension after the 3 hour incubation. Two 20 ⁇ samples of the bead supernatant recovered after the first centrifugation of the beads were spotted in a black 96 well plate for luciferase assay (unbound luciferase activity). After 3 washes with cold NP-40 lysis buffer without
  • Luciferase assay was started by adding 20 ⁇ of luciferase reaction buffer (Tricine 40mM ; (MgC0 3 ) 4 Mg(OH) 2 .5H 2 0 2,14mM ; MgS0 4 .7H 2 0 5,34mM ; DTT
  • the pRb kinase assay was performed on the cellular extract bound to the streptavidin- coated sepharose beads as described previously (Coulonval et al., supra). After 3 hours 35 of incubation at 4°C with streptavidin-coated sepharose beads, complexes were washed three times with 0.5% NP-40 lysis buffer supplemented with 1 mM DTT and three times with the kinase reaction buffer as described in Example 13.
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.5 ⁇ g of a 48- kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with occasional gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice-concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ vanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transfered on PVDF membranes (Perkin Elmer) before the phosphorylation on T826 of the pRb fragment was detected using the phospho-specific anti-pRb (T826) antibody (Thermo Fisher). Membranes were then reprobed using the H-22 polyclonal CDK4 antibody (Santa Cruz, Rabbit). An anti-rabbit or anti-mouse immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase, was used for detection by enhanced chemiluminescence (Western Lightning; Perkin- Elmer, Boston, MA).
  • Laemmli buffer glycerol 10 %
  • luciferase activity was detected on the streptavidin-coated beads incubated with extracts of MCF7 cells expressing a biotinylable luciferase together with the BirA/mCherry fusion (noted LucAvi + Be). This was not the case when the cells expressed the luciferase lacking the Avi-tag (noted Luc) or the Cyclin D3/CDK4 fusion together with the BirA/mCherry fusion (D3L2K4 + Be).
  • Biotinylated Avi-tagged Cyclin D3/CDK4 fusion protein expressed in a stable cell population of MCF7 cells after transduction with the vectors described in Example 8 is thus a perfect reporter molecule of the activation status of endogenous CDK4 described in Example 1 1.
  • Example 15 thus brings the proof of concept that a reporter molecule comprising cyclin D3/CDK4 fusion protein coupled to an Avi-tag and expressed in MCF7 together with BirA/mCherry or BirA puro fusion can be immobilized on streptavidin-coated supports and conserves an enzymatic Rb kinase activity which is modulated according to the proliferation status of the cells.
  • this reporter offers the possibility to set up a miniaturized high throughput screening assay to identify molecules or genes for instance by their silencing with siRNA, affecting the activating phosphorylation of CDK4, more particularly on T172.
  • Example 16 Purified immobilized biotinylated Avi-tagged Cyclin D3/CDK4 fusion expressed in stable cell populations of HCT116K7AS cells displays a Rb-kinase activity modulated according to their proliferation status
  • HCT1 16K7AS cells expressing the cyclin D3/CDK4 fusion protein described in the Example 14 were cultivated in 6 cm Petri dishes with 10 ml DMEM medium supplemented with 10% serum, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml). These cells express only a mutated version of CDK7 (CDK7AS) inhibitable by bulky ATP analogs such as 1 -NMPP1 (Santa Cruz).
  • the cells were rendered quiescent by incubating them for three days in DMEM without serum, but supplemented with biotin (0.1 mM), Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml). Cells were stimulated to proliferate by adding 10% serum for 5 or 16 hours in the continuous presence of biotin (0.1 mM). As indicated, vehicle (DMSO) or CDK7AS inhibitor (1 -NMPP1 ) were added together with serum for the same time or for an additionnal pulse of 1 hour. At the end of the culture, cells were washed with PBS and lysed on ice in 1 ml NP-40 lysis buffer as described in Example 10.
  • the homogenized (glass/glass) cellular lysate was sonicated 3 times and stored at -70 °C. Equal amounts of protein (corresponding to one third of the total lysate volume) from the defrozen lysate were then incubated for 3h at 4°C under slight shaking with 20 ⁇ of streptavidin-coated sepharose beads (GE Healthcare) which had been prewashed three times with NP-40 lysis buffer without inhibitors. After 3h, beads bound with transgenes were washed three times with cold NP-40 lysis buffer supplemented with 1 mM DTT without inhibitors.
  • the pRb kinase assay was performed on the cellular extract bound to the streptavidin- coated sepharose beads as described previously (Coulonval et al., supra). After 3 hours of incubation at 4°C with streptavidin-coated sepharose beads, complexes were washed three times with 0.5% NP-40 lysis buffer supplemented with 1 mM DTT and three times with the kinase reaction buffer (50 mM Hepes, pH 7.5, 10 mM KCI, 10 mM MgCI2, 2.5 mM EGTA, 1 mM DTT).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with continuous gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice-concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ vanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transfered on PVDF membranes (Perkin Elmer). The phosphorylation on T826 of the pRb fragment was detected using a phospho-specific anti-pRb (T826) antibody (Epitomics). Membranes were then reprobed using the H-22 rabbit polyclonal CDK4 antibody (Santa Cruz). An anti-rabbit immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase, was used for detection by enhanced chemiluminescence (Western Lightning; Perkin-Elmer, Boston, MA).
  • Laemmli buffer glycerol 10 %, 60 mM Tris-HCI
  • Rb kinase activity bound on streptavidin sepharose beads reporting the activity of the exogeneous biotinylatable Cyclin D3/CDK4 fusion expressed in HCT1 16K7AS cells was induced by serum as early as after 5 hours (lane 2). This induction is prevented when the CDK7AS inhibitor is present together with serum for 5 hours (lane 3). A similar inhibition by the CDK7AS inhibitor is observed when the latter is added during the last hour of a 6 hours serum stimulation period (compare lane 4 to lane 5). Maximal Rb kinase activity is detectable in HCT1 16K7AS cells expressing a biotinylatable Cyclin D3/CDK4 fusion protein after 17 hours of stimulation (lane 6). This stimulation is severely impaired when the CDK7AS inhibitor 1 -NMPP1 is added durig the last hour of serum stimulation (lane 7).
  • Example 16 thus shows that biotinylated Cyclin D3/CDK4 fusion protein expressed in HCT1 16K7AS after transduction with the vectors described in Example 8 could be purified with streptavidin-coated sepharose beads and remained enzymatically active. Finally, this activity which was heavily regulated in response to serum stimulation and inhibitable by the CDK7AS inhibitor 1 -NMPP1 perfectly mimicked the activity described in Example 15 of the biotinylated Avi-tagged Cyclin D3/CDK4 fusion protein expressed in a stable cell population of MCF7 cells after transduction with the vectors described in Example 8.
  • Example 16 thus brings the proof of concept that a reporter molecule comprising cyclin D3/CDK4 fusion protein coupled to an Avi-tag and expressed together with BirA/mCherry fusion can be immobilized on streptavidin-coated matrices and conserves an enzymatic Rb kinase activity which is modulated according to the proliferation status of the cells. This occurs in different mammalian cells.
  • this reporter offers the possibility to set up a miniaturized high throughput screening assay to identify molecules or genes for instance by their silencing with siRNAs, affecting the activating phosphorylation of CDK4, more particularly on T172. Furthermore, inhibition of the cyclin D3/CDK4 fusion protein coupled to an Avi-tag by a CDK7AS inhibitor in HCT1 16K7AS cells provides an easy internal reference to which the effects of SiRNAs or other small molecules can be advantageously compared.
  • Example 17 Mutated and wild-type biotinylatable Prescission-cleavable CCND3/CDK4 reporter expression from the constructed lentiviral vectors upon transient transfection in HEK293T cells
  • biotinylatable or non-biotinylatable cyclin D3/CDK4/EGFP or luciferase/EGFP fusion proteins separated from the Avi-tagged EGFP part of the fusion by a linker cleavable by the Prescission protease could be driven by the lentiviral constructions described in Example 8, HEK293T cells (ATCC CRL 1 1268) were transiently transfected with the corresponding DNA produced with the Qiagen midiprep kit following the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (Invitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 g/ml) and 10% foetal calf serum. 6 10 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method.
  • plasmids (1 ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours.
  • HEK293T cell culture medium supplemented with 0.1 mM biotin. Then, cells were lysed with the following buffer (100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 mM ⁇ -glycerophosphate, ⁇ g ml leupeptin, 60 ⁇ g/ml Pefabloc and 10% glycerol).
  • buffer 100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 mM ⁇ -glycerophosphate, ⁇ g ml leupeptin, 60 ⁇ g/ml Pefabloc and 10%
  • Proteins were resolved by SDS-PAGE and transferred onto PVDF membranes (Perkin Elmer) or low fluorescence PVDF membranes (Millipore) for chemiluminescence or Odyssey detection, respectively. Membranes were then probed using the anti-BirA chicken antibody (Sigma) and the mouse anti-luciferase antibody 5 (Santa Cruz). Anti-chicken immunoglobulin (Santa-Cruz) or Anti-rabbit immunoglobulin antibody (GE Healthcare), both coupled to horseradish peroxidase, were used for detection by enhanced chemiluminescence (Western Lightning, Perkin-Elmer, Boston, MA). Various exposures of the bands corresponding to these proteins were collected on Hyperfilms (GE Healthcare).
  • Mouse anti-GFP monoclonal antibody (Santa Cruz) was 10 detected with anti-mouse immunoglobulin antibody (Perbio) coupled to Dylight800 with the Odyssey system (Western Lightning; Perkin-Elmer, Boston, MA). Biotinylated proteins were detected in parallel with streptavidin coupled to AlexaFluor680 (InVitrogen) using the Odyssey system.
  • EGFP-Fusion proteins were 20 detected in all cell extracts of HEK293T except the extracts from control cells and of cells transfected with the pdLVCTEGFPtetOV5HisLuc construct. All these fusion proteins are biotinylated as revealed by detection with AlexaFluor680-labelled streptavidin.
  • Example 18 Both wild-type Prescission-cleavable and uncleavable biotinylatable CCND3/CDK4 reporters expressed from the constructed lentiviral vectors upon 25 transient transfection in HEK293T cells display Rb-kinase activity.
  • HEK293T cells (ATCC CRL 1 1268) were transiently transfected with the corresponding DNA produced with the Qiagen midiprep kit following 30 the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (Invitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 ⁇ g ml) and 10% foetal calf serum. 610 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method.
  • plasmids ( ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 35 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI "l OmM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours.
  • Tris buffer Tris 35 50mM; EDTA 1 mM
  • the pRb kinase assay was performed on the cellular extract bound to the streptavidin- coated sepharose beads (GE Healthcare) as described previously (Coulonval et al., 2003, Exp. Cell Res., 291 , 135-149). After 3 hours of incubation at 4°C with streptavidin-coated sepharose beads, complexes were washed three times with 0.5% NP-40 lysis buffer supplemented with 1 mM DTT and three times with kinase reaction buffer (50 mM Hepes, pH 7.5, 10 mM KCI, 10 mM MgCI2, 2.5 mM EGTA, 1 mM DTT).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48- kDa fragment (amino acid 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice- concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ vanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transferred on low fluorescence PVDF membranes (Millipore) before the phosphorylation on T826 of the pRb fragment was detected using a phospho-specific rabbit anti-pRb (T826) antibody (Epitomics). Total GST-Rb load of the membranes was quantitated using the mouse anti-GST antibody (Pierce). Anti-rabbit and anti-mouse immunoglobulin antibodies (Perbio) coupled to Dylight800 and Dylight680 were used for detection on the Odyssey system (Western Lightning; Perkin-Elmer, Boston, MA).
  • the cyclin D3/CDK4 fusion protein can be detected in all the extracts from HEK293T cells transfected with the indicated constructs except those from cells transfected with the constructs driving the luciferase expression used as negative controls.
  • GST-Rb fragment phosphorylation was detected both with the anti-pRb826 antibody or by the shift in apparent molecular weight observed when the western blots are probed with the anti-GST antibody only when it is incubated with extracts from HEK293T cells transfected with the constructs allowing the expression of the wild-type cyclin D3/CDK4 fusion protein.
  • a mutant cyclin D3/CDK4 fusion protein with a T172A mutation, was prepared.
  • Entry vector pENTRtopo_D3L3K4T172A (cf. SEQ ID No. 75) was used as a basis to create the final construct for HEK293 cell transfection, by recombination with the destination vector pWFAvilBC, as explained in example 8.
  • the mutant cyclin D3/CDK4T172A fusion protein was amplified using primers defined by SEQ ID No. 76 and 77.
  • the T172A mutant cyclin D3/CDK4 fusion protein expressed in the HEK293T cells transfected with the pWFAvilBC_D3L3K4T172A construct does not display Rb-kinase activity. Since this result suggests that the contribution to the Rb-kinase activity of the endogenous CDK4 eventually bound to the cyclin D3 part of the Cyclin D3-CDK4 fusion is negligible, the T172A mutant cyclin D3/CDK4 fusion protein can be used as negative control.
  • Example 19 The CDK4 moiety of a biotinylatable CCND3/CDK4 reporter expressed from the constructed lentiviral vectors upon transient transfection in HEK293T cells immobilized on streptavidin-coated beads and released by cleavage with Prescission and TEV proteases is phosphorylated on T172.
  • HEK293T cells (ATCC CRL 1 1268) were transiently transfected with the corresponding DNA vector produced with the Qiagen midiprep kit following the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (InVitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 g/ml) and 10% foetal calf serum. 6 10 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method.
  • plasmids ( ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours.
  • Tris buffer Tris 50mM; EDTA 1 mM
  • HEK293T cell culture medium supplemented with 0.1 mM biotin.
  • cells were washed with PBS, lysed on ice in 1 ml lysis buffer (100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 mM ⁇ -glycerophosphate, ⁇ g ml leupeptin, 60 ⁇ g ml Pefablock and 10% glycerol).
  • 1 ml lysis buffer 100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 mM ⁇ -glycerophosphate, ⁇ g
  • the cellular lysate was incubated at 4°C for 3 h on streptavidin-Sepharose beads (GE Healthcare) pre-washed with lysis buffer. Beads were washed 3 times with NP-40 buffer supplemented withl mM DTT, one time with the Prescission buffer (150 mM NaCI, 50 mM Tris-HCI pH 7.5, EDTA 1 mM, EGTA 1 mM) and digested by Prescission protease (GE Healthcare) overnight at 4 °C under constant mild agitation in 30 ⁇ _ Prescission digestion buffer (Prescission buffer supplemented with DTT 1 mM and 2 U Precission protease).
  • TEV protease digestion buffer 50 mM Tris-HCI pH 8, EDTA 0.5 mM, DTT 1 mM
  • 30 ⁇ _ TEV protease digestion buffer supplemented with DTT 1 mM and 4 Units of TEV protease (InVitrogen).
  • the reaction was stopped by adding an equal volume of a twice concentrated denaturation buffer.
  • Digested proteins were diluted with 300 ⁇ of denaturation buffer (7 M urea, 2 M thiourea, 4% CHAPS, 1 % DTE, 1 % Pharmalytes 3-10 (GE Healthcare) and 1 mg/ml pefablock) before being resolved by 2D gel electrophoresis separations. Proteins were separated by isoelectric focusing using the Protean IEF cell apparatus from Bio-Rad after active in-gel rehydration on immobilized linear pH gradient (pH 3 to 10) strips (GE Healthcare). After loading onto SDS-polyacrylamide slab gels (12.5%) for separation according to molecular mass, proteins were transferred to PVDF membranes (Perkin Elmer).
  • CDK4 was immunodetected first using an anti-phospho-T172-CDK4 polyclonal rabbit antibody preparation from Cell Signaling Technology (antibody no more commercially available) then using the H-22 polyclonal antibody (Santa Cruz).
  • the spot detected only by the CDK4 antibody corresponds to a CDK4 fragment with only one TEV site.
  • the non-phosphorylated CDK4 fragment bearing two TEV sites can not be detected in this assay since it probably migrates outside the range of Pharmalytes strips used (the theoretical isoelectric point is 9.1 ).
  • the two other spots correspond to acid 5 shifted phosphorylated CDK4 fragments with one or two TEV sites, respectively.
  • a more complex profile is observed when the intact cyclin D3/CDK4 fusion reporter protein is analyzed by 2D gel electrophoresis because of the complex phosphorylation of the cyclin D3 part of the fusion. Nevertheless, significant differences are noticed between the profiles of cyclin D3/CDK4 fusion reporter protein extracted from quiescent cells compared
  • cyclin D3/CDK4 fusion reporter protein is also phosphorylated on T172 as the endogeneous CDK4.
  • Prescission digested cyclin D3/CDK4 fusion reporter protein extracted from proliferating cells can be used as immunogen to generate an anti-phospho-CDK4 antibody.
  • 15 fusion reporter protein extracted from quiescent or proliferating cells can be used to identify antibodies recognizing the T172-phosphorylated form of CDK4 and characterize them.
  • Example 20 Only the wild-type Prescission-cleavable biotinylatable CCND3/CDK4 reporter constitutively expressed in MCF7 cells upon lentiviral infection displayed a 20 Rb-kinase activity.
  • lentiviruses were first produced by co-transfecting HEK293T cells with 3 ⁇ g of the lentiviral vectors constructed as described in Example 8 and 1 .5 and 3 ⁇ g of the packaging vectors pMD2.G and
  • pCMVAR8.2 25 pCMVAR8.2, respectively.
  • pMD2.G Additional plasmid #12259
  • pCMVAR8.2 Additional plasmid #12263 plasmids
  • Pr. Trono's team Universality of Lausanne, Switzerland
  • these plasmids were first precipitated together with sodium acetate and resuspended in 10 ⁇ of ultrapure DNAse-free water. The DNA mixture was added to 190 ⁇ of Tris buffer (Tris
  • HBS buffer HBS 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 .5mM.
  • 250 ⁇ of the mixture was added on 6.10 5 HEK293T cells seeded in two wells of a 6-well plate per construct, the day before transfection (2.5 ml of medium/well). Chloroquine (25 ⁇ ) was added in each well before
  • the MCF7 cells expressing the luciferase or the cyclin D3/CDK4 fusion protein described above were cultivated in 6 cm Petri dishes with 5 ml DMEM medium supplemented with biotin (0.1 mM), 5% serum, insulin 6 ng/ml, NEAA (GIBCO) 0.1 mM, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ - glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with continuous gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice-concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ orthovanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transfered on PVDF membranes (Perkin Elmer). The phosphorylation on T826 of the pRb fragment was detected using a phospho-specific anti-pRb (T826) antibody (Epitomics). An anti-rabbit immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase, was used for detection by enhanced chemiluminescence (Western Lightning; Perkin- Elmer, Boston, MA).
  • Laemmli buffer glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF,
  • Transgene expression was assessed by western blotting as described in Example 12.
  • Membranes were probed using the H-22 rabbit polyclonal CDK4 antibody (Santa Cruz), the anti-BirA chicken antibody (Sigma) and the mouse anti-luciferase antibody (Santa Cruz) or the DCS-22 monoclonal cyclin D3 antibody (Neomarkers).
  • Anti-rabbit immunoglobulin antibody GE Healthcare
  • anti-chicken antibody Sura Cruz
  • anti- mouse immunoglobulin antibody GE Healthcare
  • all coupled to horseradish peroxidase were used for detection by enhanced chemiluminescence (Western Lightning, Perkin- Elmer, Boston, MA).
  • Example 20 thus shows that Prescission-cleavable biotinylatable cyclin D3/CDK4 fusion protein expressed in MCF7 after transduction with the appropriate vectors described above could be purified with streptavidin-coated sepharose beads and remained enzymatically active. Furthermore, only beads incubated with extracts from MCF7 cells expressing a wild type biotinylatable Cyclin D3/CDK4 fusion possessed detectable Rb kinase activity. Biotinylated Avi-tagged Cyclin D3/CDK4 fusion protein expressed in a stable cell population of MCF7 cells after transduction with the vectors described in Example 8 is thus a perfect reporter molecule of the activation status of endogenous CDK4 described in Example 1 1 .
  • MCF7-AZ-V95S The MCF7 cell-lines stably transfected with the Prescission-cleavable biotinylated wild type D3L3K4 fusion and BirA Cherry (called MCF7-AZ-V95S) was deposited on September 4, 2013 at the Belgian Coordinated Collection of Microorganisms (BCCM), Ghent Belgium, under the provisional number LMBP 10330CB.
  • Example 21 CCND3/CDK4 reporters with an internal Avi-tag sequence are expressed from the constructed lentiviral vectors upon transient transfection in HEK293T cells, immobilizable on streptavidin-coated beads and enzymatically active.
  • HEK293T cells (ATCC CRL 1 1268) were transiently transfected with the indicated DNA vectors produced with the Qiagen midiprep kit following the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (Invitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 ⁇ / ⁇ ) and 10% foetal calf serum. 6 10 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method.
  • Cells were transfected with vectors encoding the different cyclin D3/CDK4 fusion reporters or reporters in which the cyclin D3/CDK4 fusion was replaced by a luciferase reporter together with a vector driving the expression of the BirA biotin ligase.
  • plasmids ( ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours.
  • Tris buffer Tris 50mM; EDTA 1 mM
  • HEK293T cell culture medium supplemented with 0.1 mM biotin. Lysates were diluted with twice-concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ orthovanadate, and protease inhibitors) and proteins were resolved by SDS-PAGE and transferred onto PVDF membranes (Perkin Elmer) or low fluorescence PVDF membranes (Millipore) for chemiluminescence or Odyssey detection, respectively.
  • Laemmli buffer glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ orthovanadate, and protease inhibitors
  • proteins were resolved by SDS-PAGE and transferred onto PVDF membranes (Perkin Elmer) or low fluorescence PVDF membranes (Millipore)
  • Membranes were then probed using the anti-BirA chicken antibody (Sigma) and the mouse anti-luciferase antibody (Santa Cruz).
  • GE Healthcare Various exposures of the bands corresponding to these proteins were collected on Hyperfilms (GE Healthcare).
  • Mouse anti-GFP monoclonal antibody was detected with anti-mouse immunoglobulin antibody (Perbio) coupled to Dylight800 with the Odyssey system (Western Lightning; Perkin-Elmer, Boston, MA).
  • Biotinylated proteins were detected in parallel with AlexaFluor 680-labelled streptavidin (InVitrogen) using the Odyssey system.
  • the pRb kinase assay was performed on the cellular extract bound to the streptavidin- coated sepharose beads (GE Healthcare) as described previously (Coulonval et al., supra).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with continuous gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice- concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ orthovanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transfered on PVDF membranes (Perkin elmer). The phosphorylation on T826 of the pRb fragment was detected using a phospho- specific anti-pRb (T826) antibody (Epitomics). An anti-rabbit immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase, was used for detection by enhanced chemiluminescence (Western Lightning; Perkin-Elmer, Boston, MA).
  • Laemmli buffer glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF
  • EGFP-Fusion proteins were detected in all cell extracts of HEK293T except the extracts from control cells, and from cells transfected with the vector driving the expression of the luciferase reporter alone or of the Avi-tagged reporters lacking the GFP moiety. All the Avi-tagged fusion proteins are biotinylated as revealed by incubation with streptavidin coupled to dye-light800. Rb-kinase activity was only detected in extracts of HEK293T cells transfected with the plasmids driving the expression of the CyclinD3/CDK4 fusion reporter proteins irrespective of the presence of the GFP fragment in the fusion.
  • Example 21 thus indicates that the internal localization of the Avi-tag does not preclude the biotinylation and immobilization on streptavidin-coated matrices of the Avi-tagged reporters. Furthermore, the presence of a GFP marker in the reporter downstream of the Avi-tagged cyclinD3/CDK4 fusion does not impede its enzymatic activity.
  • Example 22 The composition of lysis buffers influences the recovery of Rb-kinase activity of biotinylated Avi-tagged Cyclin D3/CDK4 fusion expressed in stable cell populations HCT116K7AS cell extracts immobilized on streptavidin sepharose.
  • the HCT1 16K7AS cells expressing the cyclin D3/CDK4 fusion protein described in the Example 14 were cultivated in 10 cm Petri dishes with 10 ml DMEM medium supplemented with 10% serum, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml).
  • CDK7AS CDK7 inhibitable by bulky ATP analogs
  • the cells were rendered quiescent by incubating them for three days in serum-free DMEM supplemented with biotin (0.1 mM), Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml). Cells were stimulated to proliferate by adding 10% serum for 16 hours in the continuous presence of biotin (0.1 mM). At the end of the culture, cells were washed with PBS and lysed on ice in 1 ml of the lysis buffers described in Table 6.
  • the cellular lysate were further or not homogenized (glass/glass) and/or sonicated 3 times before being stored at - 70 °C. Equal amounts of protein (corresponding to one third of the total lysate volume) from the defrozen lysate were then incubated for 3h at 4°C under slight shaking with 20 ⁇ of streptavidin-coated sepharose beads (GE Healthcare) which had been prewashed three times with NP-40 lysis buffer without inhibitors. The pRb kinase activity of the lysates was assayed on the cellular extract bound to the streptavidin-coated sepharose beads as described previously (Coulonval et al., supra).
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ - glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g/ml pefabloc, and 1 ⁇ g/ml leupeptine and incubated for 30 min at 30°C with continuous gentle agitation.
  • Reactions were stopped by adding 60 ⁇ of twice-concentrated Laemmli buffer (glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF, 100 ⁇ orthovanadate, and protease inhibitors) and boiling for 5 min. Proteins were resolved by SDS-PAGE and transfered on PVDF membranes (Perkin Elmer). The phosphorylation on T826 of the pRb fragment was detected using a phospho-specific anti-pRb (T826) antibody (Epitomics). An anti-rabbit immunoglobulin antibody (GE Healthcare) coupled to horseradish peroxidase, was used for detection by enhanced chemiluminescence (Western Lightning; Perkin- Elmer, Boston, MA).
  • Laemmli buffer glycerol 10 %, 60 mM Tris-HCI (pH 6.8), 2% SDS, 100 mM DTT, 50 mM NaF,
  • Buffer 1 to 4 allow to recover the Rb kinase activity of the exogeneous biotinylatable Cyclin D3/CDK4 fusion expressed in HCT1 16K7AS cells induced by serum even without glass/glass homogenization and/or sonication. Buffer 5 to 6 do not allow to recover any Rb kinase activity. The highest recovery of Rb kinase activity even without glass/glass homogenization and/or sonication is achieved in buffer 4 although the best discrimination between control and serum stimulated reporter Rb-kinase activity is seen with buffer 1.
  • Example 22 shows that appropriate buffers are available to extract the biotinylated Avi- tagged Cyclin D3/CDK4 fusion protein Rb-kinase of HCT1 16K7AS transduced with the vectors described in Example 8 whithout the need to homogenize or sonicate the samples.
  • Example 22 thus brings the proof of concept that the enzymatic Rb kinase activity of a reporter molecule comprising a cyclin D3/CDK4 fusion protein coupled to an Avi-tag and expressed together with BirA/mCherry fusion can be extracted without mechanical handling and immobilized on streptavidin-coated supports.
  • the extraction conditions of the enzymatic Rb kinase activity of this reporter molecule are thus compatible with the use of the reporter in miniaturized high/medium throughput screening.
  • Example 23 Alterations upon serum challenge of the cell extract Rb-kinase activity immobilized on streptavidin sepharose of biotinylated Avi-tagged Cyclin D3/CDK4 fusion expressed in stable cell populations HCT116K7AS can be detected by a dot- blot technology.
  • the HCT1 16K7AS cells expressing the cyclin D3/CDK4 fusion protein described in the Example 14 were cultivated in 10 cm Petri dishes with 10 ml DMEM medium supplemented with 10% serum, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml).
  • CDK7AS CDK7 inhibitable by bulky ATP analogs
  • the cells were rendered quiescent by incubating them for three days in DMEM without serum, but supplemented with biotin (0.1 mM), Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 ⁇ g/ml). Cells were stimulated to proliferate by adding 10% serum for 16 hours in the continuous presence of biotin (0.1 mM). At the end of the culture, cells were washed with PBS and lysed on ice in 100 ⁇ _ of the NP-40 lysis buffer.
  • Washed complexes were resuspended in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with occasional gentle agitation. Reactions were stopped by adding 400 ⁇ of ice-cold TBS buffer (NaCI 0,5M; Tris 10 mM pH 7,5).
  • Proteins were transfered on PVDP membranes using a Minifold-1 Dot-blot system (Schleicher and Schuell) before the phosphorylation on T826 of the pRb fragment was detected using a phospho-specific rabbit anti-pRb (T826) antibody (Epitomics,).
  • Total GST-Rb load of the membranes was quantitated using the mouse anti- GST antibody (Pierce).
  • An anti-rabbit and anti-mouse immunoglobulin antibody (Perbio) coupled to Dylight800 and Dylight680 were used for detection on the Odyssey system (Western Lightning; Perkin-Elmer, Boston, MA).
  • the alterations in GST-Rb phosphorylation status can be detected by a dot blot approach when the GST-Rb substrate is incubated with streptavidin- sepharose immobilized cellular extracts of HCT1 16K7AS cells expressing an exogeneous biotinylatable Cyclin D3/CDK4 reporter stimulated with serum with or without the CDK7 inhibitor 1 -NMPP1 .
  • Example 23 shows that a dot-blot technology is usable to detect the Rb-kinase activity of extracts of HCT1 16K7AS cells expressing a biotinylated Avi-tagged Cyclin D3/CDK4 fusion protein reporter after its immobilization on streptavidin sepharose.
  • Example 23 thus brings the proof of concept that the enzymatic Rb kinase activity of a reporter molecule comprising a cyclin D3/CDK4 fusion protein coupled to an Avi-tag and expressed together with BirA/mCherry fusion can be extracted without mechanical handling, immobilized on streptavidin-coated supports and detected by a method compatible with the use of the reporter in miniaturized high/medium throughput screening.
  • Example 24 Streptavidin sepharose beads have a better capacity to immobilize biotinylated Avi-tagged luciferase/GFP fusion expressed in HEK293T cells.
  • HEK293T cells (ATCC CRL 1 1268) were cultivated and transiently transfected with a plasmid encoding a non-biotinylatable luciferase reporter (pDLVCTEGFPTetOV5His luc) or a biotinylatable luciferase reporter together with a BirA/mCherry fusion protein (pWFAvilBC_Luc) as described in Example 12.
  • pDLVCTEGFPTetOV5His luc non-biotinylatable luciferase reporter
  • pWFAvilBC_Luc BirA/mCherry fusion protein
  • 50 ⁇ of the mixed lysates were then incubated for 3h at 4°C under slight shaking with 5 ⁇ of streptavidin- coated sepharose beads (GE Healthcare) which had been prewashed three times with NP-40 lysis buffer without inhibitors.
  • 50 ⁇ of mixed lysates were added on either Perkin Elmer or Pierce streptavidin-coated plates as well as on Pierce neutravidin- coated plates (. After 3h, the supernatant was collected, hen beads and plates bound with transgene were washed three times with cold NP-40 lysis buffer before enzymatic activities is measured.
  • luciferase assay two 20 ⁇ samples of the supernatant and the resuspended washed bead (bound luciferase activity) were spotted in a black 96 well plate for luciferase assay.
  • Luciferase assay was started by adding 20 ⁇ of luciferase reaction buffer (Tricine 40mM ; (MgC0 3 )4Mg(OH)2.5H 2 0 2,14mM ; MgS0 4 .7H 2 0 5,34mM ; DTT 66,6mM ; EDTA 0,2mM ; coenzyme A (40mg/50ml) ; ATP 0.7 mM ; luciferin 940 ⁇ ) and recording the emitted light for 1 sec in a Berthold luminometer.
  • Tricine 40mM (MgC0 3 )4Mg(OH)2.5H 2 0 2,14mM ; MgS0 4 .7H 2 0 5,34mM ; DTT 66,6mM ; EDTA 0,2mM ; coenzyme A (40mg/50ml) ; ATP 0.7 mM ; luciferin 940 ⁇ ) and recording the emitted light
  • Luciferase activity bound was analyzed by adding 20 ⁇ of luciferase reaction buffer (Tricine 40mM ; (MgC0 3 )4Mg(OH)2.5H 2 0 2,14mM ; MgS0 4 .7H 2 0 5,34m M ; DTT 66,6mM ; EDTA 0,2mM ; coenzyme A (40mg/50ml) ; ATP 0.7 mM ; luciferin 940 ⁇ ) and recording the emitted light for 1 sec in a Berthold luminometer.
  • Tricine 40mM (MgC0 3 )4Mg(OH)2.5H 2 0 2,14mM ; MgS0 4 .7H 2 0 5,34m M ; DTT 66,6mM ; EDTA 0,2mM ; coenzyme A (40mg/50ml) ; ATP 0.7 mM ; luciferin 940 ⁇ ) and recording the emitted
  • Example 24 shows that streptavidin beads is the support of choice to immobilize biotinylated reporters when their expression is high. With lower expression levels, Neutravidin coated plates are also adequate.
  • Example 25 The cell extract Rb-kinase activity immobilized on streptavidin sepharose of biotinylated Avi-tagged Cyclin D3/CDK4 fusion expressed in transfected HEK293T cells can be detected by a DELFIA assay.
  • HEK293T cells (ATCC CRL 1 1268) were transiently transfected with DNA vectors driving the expression of biotinylatable Cyclin D3/CDK4 or luciferase reporters fused or not to GFP.
  • Transfected DNA was produced with the Qiagen midiprep kit following the instructions of the manufacturer.
  • HEK293T cells were cultivated in DMEM medium (Invitrogen) supplemented with pyruvate (1 mM), penicillin (50 U/ml), Streptomycin (50 g/ml) and 10% foetal calf serum. 6 10 5 cells were seeded in 6-well plates the day before the transfection by the calcium phosphate method. Cells were transfected with vectors encoding the different cyclin D3/CDK4 fusion reporters or reporters in which the cyclin D3/CDK4 fusion was replaced by a luciferase reporter together with a vector driving the expression of the BirA biotine ligase.
  • plasmids ( ⁇ g each) were diluted in 200 ⁇ Tris buffer (Tris 50mM; EDTA 1 mM) supplemented with 50 ⁇ of 2,5M CaCI 2 . This dilution was added dropwise on 250 ⁇ HBS buffer (HEPES 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 ,5mM). After 10 min incubation at 37°C, 250 ⁇ of the mixture was added on the cells. DNA was left on the cells for 6 hours. Thereafter, medium was refreshed and cells were incubated for 48h in HEK293T cell culture medium supplemented with 0.1 mM biotin. Then, cells were lysed in buffer 4 as described in Example 22.
  • the DELFIA Rb-kinase assay was started by adding 5 ⁇ streptavidin-coated sepharose beads prewashed twice with NP40 lysis buffer on 100 ⁇ of cellular lysate loaded in PALL Acropreps plates and incubating the plate for 2 hours at 4°C.
  • Exogeneous streptavidin- bound biotinylatable Cyclin D3/CDK4 reporter was next resuspended in 40 ⁇ of a kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and further incubated for 30 minutes at 37 °C under mild shaking. The Rb-kinase assay was stopped after 30 minutes by adding 10 ⁇ I of EDTA 120 mM to the reaction mixture.
  • streptavidin beads were resuspended in PALL Acropreps plates with 50 ⁇ DELFIA Assay buffer (Perkin Elmer) supplemented with 0.1 % BSA. Plates were incubated overnight at 4°C under slight agitation (Vibrax shacker) with 50 ⁇ DELFIA Assay buffer (Perkin Elmer) supplemented with 0.1 % BSA and 1/1000 of the DCS-28 monoclonal cyclin D3 antibody (Santa Cruz).
  • the Rb-kinase assay was performed in parallel in the classic way on the cellular extract bound to the streptavidin-coated sepharose beads (GE Healthcare) as described previously (Coulonval et al., supra) and in the Example 21 .
  • Eu cryptate fluorescence is only detected with a Eu-labeled secondary antibody and an anti-P-Rb antibody in the Rb-kinase reaction products immobilized on gluthation-coated plates obtained with extracts of HEK293T cells transfected with vectors allowing the expression of the BirA biotin ligase fused or not to mCherry and of biotinylatable cyclin D3/CDK4 fusion reporters.
  • Example 25 brings thus the proof of concept that the DELFIA technology is thus applicable to detect Rb-kinase activity and cyclin D3/CDK4 fusion presence in extracts immobilized on streptavidin-sepharose of transfected HEK293T cells.
  • the indirect measurement of the activation of the CDK4 part of the cyclin D3/CDK4 fusion by a Rb- kinase assay is possible by the DELFIA technology and amenable to high throughput scale.
  • a suitable phospho-T172 specific anti-CDK4 antibody will be available, direct quantification of the activation of the CDK4 part of the cyclin D3/CDK4 fusion will also be possible with the DELFIA method.
  • Example 26 The cell extract Rb-kinase activity immobilized on streptavidin-coated plates of biotinylated internally Avi-tagged Cyclin D3/CDK4 fusion expressed in MCF7 cells can be detected by a DELFIA assay.
  • lentiviruses were prepared to infect MCF7 cells.
  • HEK293T cells were co-transfected with 3 ⁇ g of the lentiviral vectors constructed as described in Example 8 and 1.5 and 3 ⁇ g of the packaging vectors pMD2.G and pCMVAR8.2, respectively.
  • pMD2.G Additional plasmid #12259
  • pCMVAR8.2 Additional plasmid #12263 plasmids were described previously by Pr. Trono's team (University of Lausanne, Switzerland) (Wiznerovicz et al., supra). To this end, all plasmids were first precipitated together with sodium acetate and resuspended in 10 ⁇ of ultrapure DNAse-free water. The DNA mixture was added to 190 ⁇ of Tris buffer (Tris 50mM ; EDTA 1 mM) and 50 ⁇ of 2.5M CaCI 2 .
  • Tris buffer Tris 50mM ; EDTA 1 mM
  • HBS buffer HBS 50mM (pH 7,05) ; KCI 10mM ; dextrose 12mM ; NaCI 280mM ; Na 2 HP0 4 1 .5mM.
  • 250 ⁇ of the mixture was added on 6.10 5 HEK293T cells seeded in two wells of a 6-well plate per construct, the day before transfection (2.5 ml of medium/well).
  • Chloroquine 25 ⁇ was added in each well before incubation at 36 °C for 6 hours. Thereafter, the medium was refreshed and cells were incubated at 36 °C in 2.5 ml HEK293T cell culture medium per well.
  • MCF7 cells were harvested and filtered through a 0.45-mm low protein-binding filter (Millipore, Billerica, MA, USA). Aliquots were stored at - 70°C. Transduction of MCF7 cells cells done in triplicate, was performed by mixing 10 4 cells with 200 ⁇ viral supernatant in a 96-well plate. After 72 h, the cells were trypsinized and replicates were pooled in a 24-well plate with fresh MCF7 culture medium. Populations of MCF7 cells with inducible biotinylatable internally Avi-tagged Prescission- cleavable cyclin D3/CDK4 fusion protein or luciferase reporters fused or not to GFP were generated by successive lentiviral infection.
  • MCF7 cells were first infected with a lentivirus prepared with a vector driving the expression of the rTTA3 regulator together with the DsRed fluorescent marker.
  • the MCF7-rTTA3 cell population was amplified and enriched in red fluorescent cells on an Altra Cell Sorter (Beckton Dickinson). This purified population was next infected with a lentivirus driving the expression of the BirA biotin ligase together with the neomycin resistance gene.
  • MCF7-rTTA3-BirA cells were infected with lentiviruses prepared with vectors driving the expression of internally Avi-tagged Prescission-cleavable cyclin D3/CDK4 fusion protein or luciferase reporters fused or not to GFP together with the expression of the GFP flurescent marker (through an IRES sequence).
  • the MCF7 cells expressing the luciferase or the cyclin D3/CDK4 fusion protein described above were cultivated in 96 well microplates with 200 ⁇ DMEM medium supplemented 100 ⁇ Biotin, 5% serum, insulin 6 ng/ml, NEAA (GIBCO) 0.1 mM, Sodium pyruvate (1 mM), Penicillin (50 U/ml) and Streptomycin (50 g/ml).
  • the expression of the reporter was induced by continuous exposure to 1 ⁇ g ml doxycyclin.
  • cells were washed with PBS and lysed on ice in 400 uL lysis buffer (100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 mM ⁇ - glycerophosphate, ⁇ g ml leupeptin, 60 ⁇ g ml Pefabloc and 10% glycerol) as described in Example 10 and stored at -70 °C.
  • lysis buffer 100 mM NaCI, 50 mM Tris-HCI pH 7.5, 0.1 % SDS, 1 % Na deoxycholate, EDTA 1 mM, EGTA 1 mM, 50 mM NaF, 1 mM Orthovanadate, 1 m
  • the Rb-kinase activity was assayed on the cellular extract bound to the streptavidin- coated plates as described previously (Coulonval et al., supra). After 3 hours of incubation at 4°C, complexes were washed three times with 0.5% NP-40 lysis buffer supplemented with 1 mM DTT and three times with the kinase reaction buffer (50 mM Hepes, pH 7.5, 10 mM KCI, 10 mM MgCI2, 2.5 mM EGTA, 1 mM DTT).
  • Washed complexes were incubated in 40 ⁇ of the kinase reaction buffer containing 2 mM ATP, 0.3 ⁇ g of a 48-kDa fragment (aa 773-928) of pRb (Sigma), 10 mM ⁇ -glycerophosphate, 0.1 mM orthovanadate, 1 mM NaF, 60 ⁇ g ml pefabloc, and 1 ⁇ g ml leupeptine and incubated for 30 min at 30°C with continuous gentle agitation. The Rb-kinase assay was stopped after 30 minutes by adding 10 ⁇ of EDTA 120 mM to the reaction mixture.
  • the Rb-kinase assay product was transferred to Nunc immobilizer Gluthatione F96 clear plates (Nunc) together with 50 ⁇ DELFIA Assay buffer (Perkin elmer) supplemented with 0.1 % BSA to capture the GST-Rb fragment used as substrate in the Rb-kinase assay. Plates were incubated 1 hour at room temperature under mild shaking before being washed twice with DELFIA wash solution (Perkin Elmer). Plates were then incubated overnight at 4°C under slight agitation (Vibrax shacker) with 50 ⁇ DELFIA Assay buffer (Perkin Elmer) supplemented with 0.1 % BSA and 1/1000 anti P-RB826 antibody (Epitomics).
  • the remaining CyclinD3/CDK4 bound to the streptavidin-coated plate was incubated with 50 ⁇ DELFIA Assay buffer (Perkin Elmer) supplemented with 0.1 % BSA. Plates were incubated overnight at 4°C under slight agitation (Vibrax shacker) with 50 ⁇ DELFIA Assay buffer (Perkin Elmer) supplemented with 0.1 % BSA and 1/1000 of the DCS-28 monoclonal cyclin D3 antibody (Santa Cruz).
  • Eu cryptate fluorescence is only detected with a Eu-labeled secondary antibody and an anti-P-Rb antibody in the Rb-kinase reaction products immobilized on gluthation-coated plates obtained with extracts of MCF7 cells expressing the wild-type biotinylatable cyclin D3/CDK4 fusion reporters.
  • No phosphorylation of the GST-Rb substrate immobilized on the gluthation plates is detected with extracts of MCF7 cells expressing the biotinylatable luciferase fusion reporters.
  • Presence of Cyclin D3 was also only detected on immobilized extracts of MCF7 cells expressing the wild-type biotinylatable cyclin D3/CDK4 fusion reporters.
  • the cell population used to prepare the extract analyzed above only contained 10% of cells expressing the wild-type biotinylatable cyclin D3/CDK4 fusion reporters as judged by the proportion of cells in the population which are endowed with green fluorescence issued from the expression of EGFP fused to the cyclinD3 and CDK4. Sensitivity of the assay will be strongly enhanced when purified populations of cells will be used.
  • the Example 26 brings thus the proof of concept that the DELFIA technology is applicable to sensitively detect Rb-kinase activity and cyclin D3/CDK4 fusion presence in extracts immobilized on streptavidin-coated plates of MCF7 cell populations cultivated in 96-well plates generated by lentiviral infection and expressing the BirA biotin ligase and a biotinylatable cyclin D3/CDK4 fusion reporters.
  • Example 26 brings thus the proof of concept that the DELFIA mediated indirect measurement of the activation of the CDK4 part of the cyclin D3/CDK4 fusion by a Rb-kinase assay is sensitive enough to detect the activation of the CDK4 part of the cyclin D3/CDK4 fusion stably expressed in mammalian cells after lentiviral infection in a format amenable to high throughput.
  • Example 26 also suggests that direct detection of specific epitopes of the cyclin D3/CDK4 fusion reporter (such as the T172-phosphorylated CDK4) bound on streptavidin immobilized support is possible.
  • Such immobilized cyclin D3/CDK4 fusion reporter extracted from quiescent and phosphorylated cells could be used to differentiate antibodies able to recognize specifically the T172-phosphorylated CDK4.
  • Example 27 Use of immobilisable cyclin D/CDK4 fusion proteins as immunogen to generate anti-phospho-T172-CDK4 antibodies.
  • the cyclin D/CDK4 fusion protein can be tandemly purified from serum-stimulated eukaryotic cells and used as an immunogen to create anti-phospho CDK4 antibodies.
  • examples 25 and 26 teach that immobilized cyclinD/CDK4 fusions produced in mammalian cells cultivated in bulk or in 96-well plates can be detected using the DELFIA technology or other means known to those skilled in the art by specific antibodies such as the anti-cyclin D3 antibody.
  • example 19 teached us that cyclinD/CDK4 fusions are specifically phosphorylated on the T172 of the CDK4 part of the fusion upon serum stimulation. Combined together these teaching implicate that immobilized cyclin D/CDK4 fusions extracted from quiescent and proliferating mammalian cells and eventually digested with Precision protease can be used to discriminate molecules specifically recognizing the phosphorylated T172 form of CDK4.
  • a typical assay to identify and characterize anti-phospho CDK4 antibodies would comprise the following steps:
  • eukaryotic cells maintained in a quiescent state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hypophosphorylated form;
  • eukaryotic cells maintained in a serum stimulated state, said eukaryotic cells comprising a cyclin D/CDK4 fusion protein, wherein the CDK4 part of the fusion protein is present in a hyperphosphorylated form; isolating the cyclin D/CDK4 fusion protein from said eukaryotic cells;
  • D/CDK4 fusion protein from said serum-stimulated eukaryotic cells to said labeled secondary antibody bound to said purified or semi-purified antibody bound to the immobilized cyclin D/CDK4 fusion protein from said quiescent eukaryotic cells; selecting said purified or semi-purified antibody with quantification of the presence of said labeled secondary antibody bound to said purified or semi-purified antibody bound to the immobilized cyclin D/CDK4 fusion protein from said serum-stimulated eukaryotic cells higher than the quantification of the presence of said labeled secondary antibody to said purified or semi-purified antibody bound to the immobilized cyclin D/CDK4 fusion protein from said quiescent eukaryotic cells;
  • such an assay would be done in vivo, i.e.
  • the fusion proteins could be hyperphosphorylated due to serum-activation of the Eukaryotic cells or hypophosphorylated due to Eukaryotic cells being kept quiescent. Isolation of the fusion protein after said stimulation (or non-stimulation) would result in a hyper (or hypo) phosphorylated fusion protein, which can be immmobilised on a matrix and used to screen for and characterize antibodies specifically binding phospho-CDK4.
  • Print Out (Original in Electronic Form)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP13773628.6A 2012-09-05 2013-09-05 Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon Withdrawn EP2892918A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP13773628.6A EP2892918A2 (de) 2012-09-05 2013-09-05 Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2012067343 2012-09-05
PCT/EP2013/068399 WO2014037460A2 (en) 2012-09-05 2013-09-05 Immobilised cyclin-dependent kinase 4 fusion proteins and uses thereof
EP13773628.6A EP2892918A2 (de) 2012-09-05 2013-09-05 Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon

Publications (1)

Publication Number Publication Date
EP2892918A2 true EP2892918A2 (de) 2015-07-15

Family

ID=53275936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13773628.6A Withdrawn EP2892918A2 (de) 2012-09-05 2013-09-05 Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon

Country Status (1)

Country Link
EP (1) EP2892918A2 (de)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2014037460A2 *

Similar Documents

Publication Publication Date Title
Adhikari et al. PROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Kang et al. A general mechanism for transcription regulation by Oct1 and Oct4 in response to genotoxic and oxidative stress
Kumar et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation
Annibaldi et al. Revisiting G3BP1 as a RasGAP binding protein: sensitization of tumor cells to chemotherapy by the RasGAP 317–326 sequence does not involve G3BP1
Murshid et al. Protein kinase A binds and activates heat shock factor 1
Liu et al. Merkel cell polyomavirus large T antigen disrupts lysosome clustering by translocating human Vam6p from the cytoplasm to the nucleus
Ohashi et al. The EBNA3 family of Epstein-Barr virus nuclear proteins associates with the USP46/USP12 deubiquitination complexes to regulate lymphoblastoid cell line growth
Nouri et al. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion
Rivera et al. Xenopus Shugoshin 2 regulates the spindle assembly pathway mediated by the chromosomal passenger complex
Cao et al. Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2
Fullam et al. DDX3 directly facilitates IKKα activation and regulates downstream signalling pathways
Ampofo et al. CK2 phosphorylation of human Sec63 regulates its interaction with Sec62
Ide et al. Guanine nucleotide exchange factor DOCK11-binding peptide fused with a single chain antibody inhibits hepatitis B virus infection and replication
US20150299764A1 (en) Immobilised cyclin-dependent kinase 4 fusion proteins and uses thereof
Quaresma et al. Human hnRNP Q re-localizes to cytoplasmic granules upon PMA, thapsigargin, arsenite and heat-shock treatments
Zhang et al. PLK1-dependent phosphorylation restrains EBNA2 activity and lymphomagenesis in EBV-infected mice
Miller et al. Identification of serine 205 as a site of phosphorylation on Pax3 in proliferating but not differentiating primary myoblasts
Danciu et al. The basic helix loop helix transcription factor Twist1 is a novel regulator of ATF4 in osteoblasts
Amin et al. CLIP-170 tethers kinetochores to microtubule plus ends against poleward force by dynein for stable kinetochore–microtubule attachment
CA3073375A1 (en) Fusion protein of dctn1 protein with ret protein
Li et al. Co‐activator activator (CoAA) prevents the transcriptional activity of Runt domain transcription factors
EP2892918A2 (de) Immobilisierte cyclin-abhängige kinase-4-fusionsproteine und verwendungen davon
Fischer et al. Differential tyrosine phosphorylation controls the function of CNK1 as a molecular switch in signal transduction
Kumar et al. Dynamics of physical interaction between HIV-1 Nef and ASK1: identifying the interacting motif (s)
Fioretti et al. Crosstalk between 14-3-3θ and AF4 enhances MLL-AF4 activity and promotes leukemia cell proliferation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150402

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20180420

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20180831